<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Biol Sex Differ</journal-id>
<journal-id journal-id-type="iso-abbrev">Biol Sex Differ</journal-id>
<journal-title-group>
<journal-title>Biology of Sex Differences</journal-title>
</journal-title-group>
<issn pub-type="epub">2042-6410</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32223745</article-id>
<article-id pub-id-type="pmc">7104511</article-id>
<article-id pub-id-type="publisher-id">283</article-id>
<article-id pub-id-type="doi">10.1186/s13293-020-0283-1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuroprotective and neurotoxic outcomes of androgens and estrogens in an oxidative stress environment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Duong</surname>
<given-names>Phong</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tenkorang</surname>
<given-names>Mavis A. A.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Trieu</surname>
<given-names>Jenny</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McCuiston</surname>
<given-names>Clayton</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rybalchenko</surname>
<given-names>Nataliya</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5984-5516</contrib-id>
<name>
<surname>Cunningham</surname>
<given-names>Rebecca L.</given-names>
</name>
<address>
<email>rebecca.cunningham@unthsc.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.266871.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9765 6057</institution-id><institution>Department of Physiology and Anatomy, Institute for Healthy Aging, </institution><institution>University of North Texas Health Science Center, </institution></institution-wrap>Fort Worth, TX 76107 USA </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.266871.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9765 6057</institution-id><institution>Texas College of Osteopathic Medicine, </institution><institution>University of North Texas Health Science Center, </institution></institution-wrap>Fort Worth, TX 76107 USA </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.266871.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9765 6057</institution-id><institution>Department of Pharmaceutical Sciences, UNT System College of Pharmacy, </institution><institution>University of North Texas Health Science Center, </institution></institution-wrap>3400 Camp Bowie Boulevard, Fort Worth, TX 76107 USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>29</day>
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>29</day>
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<elocation-id>12</elocation-id>
<history>
<date date-type="received">
<day>3</day>
<month>9</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2020</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p id="Par1">The role of sex hormones on cellular function is unclear. Studies show androgens and estrogens are protective in the CNS, whereas other studies found no effects or damaging effects. Furthermore, sex differences have been observed in multiple oxidative stress-associated CNS disorders, such as Alzheimer’s disease, depression, and Parkinson’s disease. The goal of this study is to examine the relationship between sex hormones (i.e., androgens and estrogens) and oxidative stress on cell viability.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">N27 and PC12 neuronal and C6 glial phenotypic cell lines were used. N27 cells are female rat derived, whereas PC12 cells and C6 cells are male rat derived. These cells express estrogen receptors and the membrane-associated androgen receptor variant, AR45, but not the full-length androgen receptor. N27, PC12, and C6 cells were exposed to sex hormones either before or after an oxidative stressor to examine neuroprotective and neurotoxic properties, respectively. Estrogen receptor and androgen receptor inhibitors were used to determine the mechanisms mediating hormone-oxidative stress interactions on cell viability. Since the presence of AR45 in the human brain tissue was unknown, we examined the postmortem brain tissue from men and women for AR45 protein expression.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">Neither androgens nor estrogens were protective against subsequent oxidative stress insults in glial cells. However, these hormones exhibited neuroprotective properties in neuronal N27 and PC12 cells via the estrogen receptor. Interestingly, a window of opportunity exists for sex hormone neuroprotection, wherein temporary hormone deprivation blocked neuroprotection by sex hormones. However, if sex hormones are applied following an oxidative stressor, they exacerbated oxidative stress-induced cell loss in neuronal and glial cells.</p>
</sec>
<sec>
<title>Conclusions</title>
<p id="Par4">Sex hormone action on cell viability is dependent on the cellular environment. In healthy neuronal cells, sex hormones are protective against oxidative stress insults via the estrogen receptor, regardless of sex chromosome complement (XX, XY). However, in unhealthy (e.g., high oxidative stress) cells, sex hormones exacerbated oxidative stress-induced cell loss, regardless of cell type or sex chromosome complement. The non-genomic AR45 receptor, which is present in humans, mediated androgen’s damaging effects, but it is unknown which receptor mediated estrogen’s damaging effects. These differential effects of sex hormones that are dependent on the cellular environment, receptor profile, and cell type may mediate the observed sex differences in oxidative stress-associated CNS disorders.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Neuroprotection</kwd>
<kwd>Neurodegeneration</kwd>
<kwd>Membrane androgen receptor</kwd>
<kwd>AR45</kwd>
<kwd>Window of opportunity</kwd>
<kwd>Estrogen receptors</kwd>
<kwd>Oxidative stress</kwd>
<kwd>Human hippocampus</kwd>
<kwd>Estrogen</kwd>
<kwd>Testosterone</kwd>
<kwd>Sex differences</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id>
<institution>National Institute of Neurological Disorders and Stroke</institution>
</institution-wrap>
</funding-source>
<award-id>NS0091359</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par5">Sex differences have been of interest as far back as 1871 with Charles Darwin’s publication titled “The descent of man, and selection in relation to sex” [<xref ref-type="bibr" rid="CR1">1</xref>]. Unfortunately, the number of studies on sex differences is sparse; leading to the National Institutes of Health (NIH) 2015 requirement of sex to be examined in NIH-funded studies. Further knowledge of sex differences is necessary as medicine is moving toward individualized precision medicine [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
<p id="Par6">Numerous CNS disorders exhibit sex differences, which may result in the need for sex-specific standard of care. Men have an increased risk for Parkinson’s disease [<xref ref-type="bibr" rid="CR3">3</xref>], autism [<xref ref-type="bibr" rid="CR4">4</xref>], and schizophrenia [<xref ref-type="bibr" rid="CR5">5</xref>]. Conversely, Alzheimer’s disease [<xref ref-type="bibr" rid="CR6">6</xref>], major depression [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], and stress disorders [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>] are more prevalent in women than men. Menopause in women also influences the prevalence of CNS disorders, such as Alzheimer’s disease [<xref ref-type="bibr" rid="CR11">11</xref>], stroke [<xref ref-type="bibr" rid="CR12">12</xref>], Parkinson’s disease [<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR15">15</xref>], depression [<xref ref-type="bibr" rid="CR16">16</xref>], anxiety disorders [<xref ref-type="bibr" rid="CR17">17</xref>], and schizophrenia [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. During menopause, estradiol levels abruptly decline from 15–350 pg/ml (depending on menstrual cycle stage) to less than 10 pg/ml, which is below circulating estradiol levels in men (10–40 pg/ml) [<xref ref-type="bibr" rid="CR20">20</xref>]. Interestingly, testosterone levels (8–60 ng/dL) are maintained in women during menopause [<xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR23">23</xref>]; these testosterone levels are 27–30 fold less than the levels observed in healthy young adult men (240–950 ng/dL) and middle-aged men (219–929 ng/dL) [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p>
<p id="Par7">Both androgens (i.e., testosterone and dihydrotestosterone, DHT) and estrogens (i.e., 17β-estradiol) along with their cognate receptors can influence the CNS by altering both structure and function [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Within the past 25 years, studies have examined sex differences in androgen and estrogen receptor expression in the brain, such as the hypothalamus, cortex, and hippocampus (Table <xref ref-type="table" rid="Tab1">1</xref>). Generally, sex hormones have protective effects in the CNS [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. However, recent findings indicate that the effects of sex hormones may depend on the cell type, cellular environment, and receptor expression profile [<xref ref-type="bibr" rid="CR38">38</xref>–<xref ref-type="bibr" rid="CR41">41</xref>]. Further, most studies only examined full-length androgen receptors, using antibodies (i.e., PG-21, Santa Cruz N-20, and Chemicon Ab561) that target amino acid sequences in the N terminus region of the androgen receptor (Table <xref ref-type="table" rid="Tab1">1</xref>). These antibodies are unable to indicate the presence of an androgen receptor variant (i.e., AR45) that is missing the regulatory N terminus domain [<xref ref-type="bibr" rid="CR42">42</xref>].
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Sex differences in steroid hormone receptor expression profile in the CNS</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Receptor</th><th>Structure</th><th>Female: male expression</th><th>Citation</th></tr></thead><tbody><tr><td colspan="4">Androgen receptor—N terminal domain</td></tr><tr><td rowspan="11"></td><td>Bed nucleus stria terminalis (adult, rat)</td><td>Male</td><td>[<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td>Cortex (PD 28 and adult, mice)</td><td>No difference</td><td>[<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td>Hippocampus (PD 28, mice)</td><td>Male</td><td>[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td>Hypothalamus (adult, mice)</td><td>Male</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td>Lateral septum (adult, mice)</td><td>Male</td><td>[<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td>Mammillary nucleus (adult, human)</td><td>Male</td><td>[<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td>Medial preoptic area (adult, mice)</td><td>Male</td><td>[<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td>Periventricular nucleus (adult, rat)</td><td>Male</td><td>[<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td>Spinal motor neurons (adult, rat)</td><td>No difference</td><td>[<xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td>Substantia nigra pars Compacta (PD 30, rat)</td><td>No difference</td><td>[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td>Substantia nigra pars reticulata (PD 30, rat)</td><td>Female</td><td>[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td colspan="4">Estrogen receptor α</td></tr><tr><td rowspan="5"></td><td>Cortex (PD 28, mice)</td><td>Male</td><td>[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td>Hippocampus (PD 28, mice)</td><td>No difference</td><td>[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td>Hypothalamus (adult, mice)</td><td>Female</td><td>[<xref ref-type="bibr" rid="CR35">35</xref>]</td></tr><tr><td>Substantia nigra pars compacta (PD 30, rat)</td><td>No difference</td><td>[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td>Substantia nigra pars reticulata (PD 30, rat)</td><td>Female</td><td>[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td colspan="4">Estrogen receptor β</td></tr><tr><td rowspan="4"></td><td>Cortex (PD 28, mice)</td><td>Female</td><td>[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td>Hippocampus (PD 28, mice)</td><td>Female</td><td>[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td>Substantia nigra pars compacta (PD 30, rat)</td><td>Female</td><td>[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td>Substantia nigra pars reticulata (PD 30, rat)</td><td>No difference</td><td>[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr></tbody></table></table-wrap></p>
<p id="Par8">The AR45 localizes to plasma membrane lipid rafts in multiple brain regions, such as the entorhinal cortex, the hippocampus, and the substantia nigra [<xref ref-type="bibr" rid="CR42">42</xref>], and is present in the human postmortem brain tissue (Fig. <xref ref-type="fig" rid="Fig1">1</xref>c). This androgen receptor variant is unresponsive to classical androgen receptor antagonists and involved in non-genomic actions of androgens [<xref ref-type="bibr" rid="CR43">43</xref>]. Specifically, AR45 interacts with G proteins and the NADPH oxidase (NOX) signaling pathways, which can lead to increased oxidative stress and cell loss [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].
<fig id="Fig1"><label>Fig. 1</label><caption><p>Expression profile of hormone receptors. N27, PC12, C6, and MCF7 cells express the androgen receptor splice variant, AR45, and not full-length androgen receptors. In contrast, Jurkat cells express the full-length androgens receptor but not the AR45, which indicate that Jurkat cells are useful as both positive control and negative control for full-length androgen receptors and AR45, respectively (<bold>a</bold>, <bold>b</bold>). AR45 protein is expressed in human hippocampal tissue (<bold>c</bold>). Using the C terminus domain androgen receptor antibody, AR-C19, AR45 expression was detected in the membrane fraction and the whole cell lysate of frozen hippocampal postmortem tissue obtained from donors diagnosed with Alzheimer’s disease. No significant differences were observed between AR45 expression in whole cell lysate versus the membrane fraction, indicating AR45 is a membrane-associated androgen receptor. As expected, full-length androgen receptors (110 kDa) were not observed in frozen samples. However, an androgen receptor fragment (70 kDa) was observed in whole cell lysate, indicating the full-length androgen receptor that resides in the cytosol and nucleus was degraded to fragments. To confirm AR45 protein expression, which is missing the N terminus domain (NTD), the AR-N20 NTD targeted androgen receptor antibody was used. No AR45 expression was detected with AR-N20 antibody. Results were determined by ANOVA. Results are reported as mean <underline>+</underline> SEM. <italic>p</italic> &lt; 0.05; WCL, whole cell lysate; MEM, membrane fraction; AR, androgen receptor</p></caption><graphic id="MO1" xlink:href="13293_2020_283_Fig1_HTML"></graphic></fig></p>
<p id="Par9">Oxidative stress results from the dysregulation of free radical homeostasis, which can damage lipids, proteins, and DNA. Free radicals are molecules that contain unpaired electrons and play important roles in cellular function (e.g., signal transduction and gene transcription) [<xref ref-type="bibr" rid="CR43">43</xref>]. The most common free radicals are hydroxyls, superoxides, and nitric oxide, which can produce hydrogen peroxide and peroxynitrate. Further, the most common reactive oxygen species (ROS) that produce free radicals are hydrogen peroxide and peroxynitrate. These free radicals and ROS are primarily generated via mitochondrial aerobic metabolism to create energy (ATP production) [<xref ref-type="bibr" rid="CR44">44</xref>].</p>
<p id="Par10">The brain is the highest consumer of energy in the body, in which it uses 20% of available energy for cellular communication and housekeeping functions [<xref ref-type="bibr" rid="CR45">45</xref>]. Under normal physiological conditions, ~ 2% of oxygen used to generate ATP is converted to ROS. In unhealthy or aged brains, more oxygen is converted to ROS [<xref ref-type="bibr" rid="CR46">46</xref>], increasing the susceptibility of the brain to oxidative stress and damage. Oxidative damage can result in chronic diseases and has been shown to be associated with CNS diseases, such as Parkinson’s disease [<xref ref-type="bibr" rid="CR47">47</xref>], autism [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>], schizophrenia [<xref ref-type="bibr" rid="CR50">50</xref>], Alzheimer’s disease [<xref ref-type="bibr" rid="CR51">51</xref>], stroke [<xref ref-type="bibr" rid="CR52">52</xref>], major depression [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>], and anxiety disorders [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Since sex differences are observed in these oxidative stress-associated CNS disorders and it is unclear what impact androgens and estrogens have on oxidative stress signaling, it is important to examine the relationship between sex hormones and oxidative stress.</p>
<p id="Par11">In these studies, we focused on N27 neuronal-derived female rat cells, PC12 neuronal phenotype male rat cells, and C6 glial-derived male rat cells. These cell lines express estrogen receptors α/β and AR45, but do not express the full-length androgen receptor (Fig. <xref ref-type="fig" rid="Fig1">1</xref>a, b). These cell lines will allow further investigation of the effects of the novel androgen receptor variant, AR45, on cell survival. We chose to examine AR45 over the full-length androgen receptor as our prior studies found no effects of androgen receptor antagonists on oxidative stress endpoints, such as cell viability [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p>
</sec>
<sec id="Sec2">
<title>Materials and methods</title>
<sec id="Sec3">
<title>Reagents</title>
<p id="Par12">Fetal bovine serum (FBS, 35-010-CV), Dulbecco’s modified Eagle’s medium (DMEM, 10-017-CV), and <sc>l</sc>-glutamine (25-005-CI) were purchased from Corning. Charcoal/dextran-stripped fetal bovine serum (CS-FBS, S11650) was purchased from Atlanta Biologicals. DMSO (D128), SuperSignal West Femto Substrate (34096), Pierce BCA Protein Assay Kit (23225), tris-buffered saline (TBS, BP2471), and Tween-20 (BP337) were purchased from Thermo Fisher Scientific. Penicillin-streptomycin solution (PS, 15140-122), phosphate-buffered saline (PBS, 10010-031), and TrypLE Select LE 10X (A12177-01) were purchased from Gibco. Androgen receptor degrader ASC-J9 (J9, HY-15194) was purchased from MedChem Express. ICI 182,780 (ICI, 1047) and Androgen R/NR3C4 (MAB5876) were purchased from R&amp;D Systems. Actin (ADI-CSA-400) was purchased from Enzo Life Sciences. <italic>tert-</italic>Butyl hydroperoxide (H<sub>2</sub>O<sub>2</sub>, A13926) and thiazolyl blue tetrazolium bromide solution (MTT, L11939) were purchased from Alfa Aesar. RPMI-1640 medium (SH30027.02) and RPMI-1640 Phenol Red and <sc>l</sc>-glutamine-free medium (SH30605.01) were purchased from Hyclone. 4-Androsten-17β-ol-3-one (testosterone, A6950-000) and dihydrotestosterone 3-CMO: BSA (DHT-BSA, A2574-050) were purchased from Steraloids. 17β-Estradiol (E-8875) and NGF (N0513) were purchased from Millipore Sigma. The antibodies AR-C19 (SC-815), AR-N20 (SC-816), ERα (SC-542), and ERβ (SC-8974) were purchased from Santa Cruz Biotechnology. GAPDH (GTX627408) was purchased from GeneTex, and goat anti-rabbit (31460) and goat anti-mouse (31430) secondary antibodies were purchased from Invitrogen. NP40 lysis buffer (J619-500) was purchased from Ameresco. RIPA lysis buffer (N653) was purchased from VWR. 15-well/15 uL any KD mini protean gels (456-9036) and Immun-Blot PVDF membranes (162-0177) were purchased from Bio-Rad.</p>
</sec>
<sec id="Sec4">
<title>Human cases</title>
<p id="Par13">Frozen hippocampal postmortem tissue from male and female donors, aged 66–93, Caucasian, was obtained from the Institute for Healthy Aging’s Brain Bank at the University of North Texas Health Science Center. Tissue storage period was less than 9 years. All cases exhibited Alzheimer’s disease-associated pathology.</p>
</sec>
<sec id="Sec5">
<title>Cell culture</title>
<p id="Par14">This study used only rat-based cell lines in our experimental procedures. 1RB3AN27 (N27) dopaminergic cells (kind gift from Randy Strong, Ph.D., at University of Texas Health Science Center; RRID: CVCL_D584), PC12 dopaminergic adherent cells (ATCC CRL-1721.1; RRID: CVCL_F659), and C6 glial cells (ATCC CCL-107; RRID: CVCL_0194) were used in experimental paradigms. N27 cells are derived from SV40 T antigen-transformed neurons originally from embryonic female rat mesencephalic cells [<xref ref-type="bibr" rid="CR57">57</xref>]. PC12 neuroblastic cells are derived from a pheochromocytoma from a male rat [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. C6 glioma cells were derived from the male rats [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. N27 and PC12 cells were grown in RPMI-1640 media supplemented with 10% FBS and 1% PS (culture media). Although the adherent PC12 cells do not require NGF differentiation for adherence, dopaminergic neuronal phenotype, and response to oxidative stressors [<xref ref-type="bibr" rid="CR62">62</xref>], we added NGF (100 ng/ml) to the PC12 media at time of plating [<xref ref-type="bibr" rid="CR63">63</xref>]. C6 cells were originally propagated in DMEM supplemented with 10% FBS and 1% PS. Following 48 h of growth, C6 cells were switched to the RPMI culture media. There were no significant differences observed in function or morphology following the medium switch in C6 cells (unpublished observation). Cells were maintained in a sterile environment at 37 <sup>o</sup>C with 5% CO<sub>2</sub> and sub-cultured every 2–3 days.</p>
<p id="Par15">To ensure the quality and integrity of the different cell lines, all experiments were conducted between passages 16–21 (undifferentiated N27), 8–14 (undifferentiated C6), and 5–10 (differentiated PC12). We also characterized these cells based on their morphology, doubling time, and a well-characterized response to tert-butyl hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and testosterone [<xref ref-type="bibr" rid="CR39">39</xref>–<xref ref-type="bibr" rid="CR41">41</xref>]. Cell lines were switched to RPMI 1640 serum-free media supplemented with 10% CS-FBS and 1% PS (experimental media) prior to induction of experimental compounds to avoid hormonal content found within regular FBS [<xref ref-type="bibr" rid="CR39">39</xref>–<xref ref-type="bibr" rid="CR41">41</xref>]. CS-FBS does not contain steroid hormones (i.e., estradiol, testosterone, thyroid hormones). Testosterone, estradiol, and DHT-BSA were from stock solutions made in DMSO (final DMSO concentration &lt; 0.001%).</p>
</sec>
<sec id="Sec6">
<title>Cell culture treatments</title>
<p id="Par16">Reported LC-MS/MS brain hormone levels in male rats are (1) 5–24 nM testosterone [<xref ref-type="bibr" rid="CR64">64</xref>–<xref ref-type="bibr" rid="CR67">67</xref>], (2) 2.3–3.2 nM DHT [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR67">67</xref>], and 0.2–0.9 nM estradiol [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. Since little to no albumin is present in healthy brains [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>], brain hormones are not protein bound and considered free. In order to compensate for the albumin (2.1 g/dl) in the CS-FBS, we used the Vermeulen calculation to determine the appropriate hormone dosage to attain physiological brain hormone levels [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. Therefore, in CS-FBS 100 nM, testosterone is 8 nM calculated free testosterone, 1 nM estradiol is 0.07 nM calculated free estradiol, and 500 nM DHT-BSA is 24 nM calculated free DHT-BSA. The higher DHT-BSA dosage was used to compensate for decreased hormone binding due to the 20 DHT molecules per 1 BSA molecule composition of DHT-BSA [<xref ref-type="bibr" rid="CR39">39</xref>]. Based on this, the levels of hormones used in this study are a reasonable approximation of brain hormone levels.</p>
<p id="Par17">N27 and C6 cells were plated onto 96-well plates at a density of 1.5–2.0 × 10<sup>6</sup> cells/mL with culture media, whereas PC12 cells were plated at 6.0 × 10<sup>4</sup> cells/mL in culture media. All cells were left to proliferate overnight, except for PC12 cells that required 48 h. For treatments under the neuroprotective paradigm, cells were exposed to testosterone [<xref ref-type="bibr" rid="CR72">72</xref>], 17β-estradiol, and DHT-BSA in experimental media (i.e., CS-FBS) for 2 h. Following the hormone exposure, N27 cells were treated with 15–20 uM of H<sub>2</sub>O<sub>2</sub> in experimental media, PC12 cells with 30 uM of H<sub>2</sub>O<sub>2</sub> in experimental media, and C6 cells with 50 uM of H<sub>2</sub>O<sub>2</sub> in experimental media for 18 h to induce 20–30% cell loss. Cells under the neurotoxic paradigm underwent 10–20 uM (N27), 30 uM (PC12), or 50 uM (C6) of H<sub>2</sub>O<sub>2</sub> for 2 h to induce 20–30% cell loss before hormone exposure for an additional 18 h. Cell viability was determined following each treatment paradigm.</p>
</sec>
<sec id="Sec7">
<title>Hormone receptor inhibitors</title>
<p id="Par18">The estrogen receptor α/β inhibitor, ICI 182, 780 (ICI), and the androgen receptor degrader, ASC-J9 (J9), were used for this study. Inhibitor dose was chosen based on the IC<sub>50</sub> data. Inhibitors and the degrader were made from stock solutions in DMSO (final DMSO concentration &lt; 0.001%). For paradigms involving hormone receptor inhibitors, cells were exposed to ICI (300 pM) in experimental media for 1 h prior to induction of any hormones or oxidative stressor. For the androgen receptor degrader, J9 (5 uM), cells were exposed to the degrader for 30 min followed by either hormones or oxidative stressor for 1 h. Cells were then treated with either hormones or oxidative stressor for an additional 2 h.</p>
</sec>
<sec id="Sec8">
<title>Cell viability</title>
<p id="Par19">Cell viability was determined by MTT assay. Media was aspirated from all wells, replenished with 100 uL of RPMI-1640 phenol red-free medium, and supplemented with 10% CS-FBS, 1% PS, and 1% <sc>l</sc>-glutamine. This was followed by the addition of 20 uL of 5 mg/mL of MTT solution to each well. Experimental plates were then covered in foil to block additional light and incubated at 37 <sup>o</sup>C with 5% CO<sub>2</sub> for 3 h. Following incubation, plates were read at an absorbance of 595 nm. The colorimetric intensity is directly proportional to the number of viable cells in each well. Readings from respective treatment groups were then normalized to the vehicle control group to determine cell viability [<xref ref-type="bibr" rid="CR39">39</xref>–<xref ref-type="bibr" rid="CR41">41</xref>]. Three independent experiments, using different cell cultures, were conducted.</p>
</sec>
<sec id="Sec9">
<title>Western blot analysis</title>
<p id="Par20">In order to confirm hormone receptor expression (Fig. <xref ref-type="fig" rid="Fig1">1</xref>), untreated N27, PC12, and C6 cells were collected and homogenized. We included Jurkat whole cell lysate (Abcam ab7899) as a positive control for the full-length androgen receptor and estrogen receptors α/β, and the MCF7 breast cancer cell line (ATCC HTB-22; RRID: CVCL_0031) was used as a positive control for estrogen receptors α/β. Additionally, we examined androgen receptor expression in human hippocampal tissues (25–50 ug). Tissues were homogenized using a RIPA lysis buffer mixture supplemented with protease inhibitor cocktail, 1 uM DTT, and 1 mM EDTA. Following homogenization and separation into whole cell lysate and membrane fractions [<xref ref-type="bibr" rid="CR42">42</xref>], protein concentrations were determined using the Pierce BCA Protein Assay Kit per manufacturer’s instructions. Equal amounts of protein (20 ug) were separated in a Bio-Rad Any KD polyacrylamide gel at 25 mA for approximately 1 h and transferred onto a PVDF membrane at 50 V at 4 <sup>o</sup>C for 2–3 h. Following transfer, membrane blots were blocked using 5% non-fat milk in TBST for 30 min at room temperature. After blocking, membranes were incubated with constant agitation in primary antibodies (ERα 1:1000, ERβ 1:1000, ARC19 1:1000 for cell lines, Androgen R/NR3C4 1:1000 and ARN20 1:1000 for human tissue, Actin 1:1000, and GAPDH 1:10000) in 1% TBST non-fat milk either 2 h at room temperature or overnight at 4 <sup>o</sup>C. Membranes were then washed with 10% TBST twice for 10 min each before being incubated with secondary antibodies (Goat Anti-Rb HRP 1:1000 and Goat Anti-Ms HRP 1:10000) in 1% TBST non-fat milk for 30 min at room temperature. Afterwards, membranes were washed with 10% TBST two times for 10 min each. Visualization of bands was performed using SuperSignal West Femto Maximum Sensitivity Substrate and imaged for 30–90 s. Band intensity was then quantified by densitometry using the National Institutes of Health ImageJ program and normalized to GAPDH or actin levels. Three independent experiments were used.</p>
</sec>
<sec id="Sec10">
<title>Statistical analysis</title>
<p id="Par21">Analyses were performed using IBM SPSS Statistics version 21 software. Statistical comparisons were made by two or three-way ANOVA using oxidative stressor (H<sub>2</sub>O<sub>2</sub>), hormones (testosterone, 17β-estradiol, DHT-BSA), and inhibitors as independent factors. This was followed by Fisher’s LSD post hoc analysis to evaluate differences between groups. Results are expressed as mean± SEM, and <italic>p</italic> value less than or equal to 0.05 (<italic>p</italic>≤ 0.05) indicates statistically significant differences. Each experiment was replicated at least three times using different cell cultures.</p>
</sec>
</sec>
<sec id="Sec11">
<title>Results</title>
<sec id="Sec12">
<title>Testosterone and 17β-estradiol are protective in N27 and PC12 cells but not C6 cells</title>
<p id="Par22">In vitro testosterone-mediated neuroprotection has been observed in several neuronal cells, including N27 cells [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Similarly, in this study, we observed significant effects of the oxidative stressor H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 8</sub> = 475.2, <italic>η</italic><sup>2</sup> = 0.94, <italic>p</italic> &lt; 0.05) and the hormone testosterone (<italic>F</italic><sub>1, 8</sub> = 13.8, <italic>η</italic><sup>2</sup> = 0.03, <italic>p</italic> &lt; 0.05) on cell viability, along with an interaction between H<sub>2</sub>O<sub>2</sub> and testosterone (<italic>F</italic><sub>1, 8</sub> = 8.7, <italic>η</italic><sup>2</sup> = 0.02, <italic>p</italic> &lt; 0.05). Two-hour pretreatment of N27 cells with testosterone (100 nM) prior to oxidative stress, protected the cells by attenuating H<sub>2</sub>O<sub>2</sub>-induced cell loss (Fig. <xref ref-type="fig" rid="Fig2">2</xref>a). Consistent with our prior studies, testosterone alone did not have any effect on cell viability [<xref ref-type="bibr" rid="CR39">39</xref>–<xref ref-type="bibr" rid="CR41">41</xref>].
<fig id="Fig2"><label>Fig. 2</label><caption><p>An effect of hormone pretreatment in N27 and C6 cells in the presence of oxidative stress. Hormone alone has no effect on cell viability. H<sub>2</sub>O<sub>2</sub> decreased the cell viability by ~ 20–30%. Testosterone and 17β-estradiol pretreatment prior to H<sub>2</sub>O<sub>2</sub> is protective in N27 cells (<bold>a</bold>, <bold>b</bold>) and not in C6 cells (<bold>d</bold>, <bold>e</bold>). DHT-BSA, followed by H<sub>2</sub>O<sub>2</sub> exposure, did not protect N27 and C6 cells in an oxidative stress environment (<bold>c</bold>, <bold>f</bold>). Results were determined by ANOVA followed by Fisher LSD post hoc test. Results are reported as mean <underline>+</underline> SEM. <italic>p</italic> &lt; 0.05; *versus control, **versus H<sub>2</sub>O<sub>2</sub>. C, vehicle control; T, 100 nM testosterone; H, H<sub>2</sub>O<sub>2</sub>; TH, pre-treatment T. E, 1 nM 17β-estradiol; EH, pre-treatment E; D, 500 nM DHT-BSA; DH, pre-treatment D</p></caption><graphic id="MO2" xlink:href="13293_2020_283_Fig2_HTML"></graphic></fig></p>
<p id="Par23">To examine if 17β-estradiol protects against oxidative stress damage, N27 cells were pretreated with 17β-estradiol, followed by H<sub>2</sub>O<sub>2</sub>. Significant effects of oxidative stressor H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 8</sub> = 56.2, <italic>η</italic><sup>2</sup> = 0.64, <italic>p</italic> &lt; 0.05) and 17β-estradiol (<italic>F</italic><sub>1, 8</sub> = 11.2, <italic>η</italic><sup>2</sup> = 0.13, <italic>p</italic> &lt; 0.05), along with an interaction between H<sub>2</sub>O<sub>2</sub> and estradiol (<italic>F</italic><sub>1, 8</sub> = 12.5, <italic>η</italic><sup>2</sup> = 0.14, <italic>p</italic> &lt; 0.05) on cell viability, were observed (Fig. <xref ref-type="fig" rid="Fig2">2</xref>b).</p>
<p id="Par24">Unlike testosterone and 17β-estradiol, DHT-BSA did not alter H<sub>2</sub>O<sub>2</sub>-induced cell loss in N27 cells (Fig. <xref ref-type="fig" rid="Fig2">2</xref>c). DHT and 17β-estradiol are testosterone metabolites, which are ligands for the androgen receptor and the estrogen receptor, respectively. The addition of the BSA molecule to DHT restricts its activity to membrane androgen receptors. These results indicate that the putative membrane-associated androgen receptor does not mediate steroid hormone neuroprotection against oxidative stress insults, suggesting that the estrogen receptor mediates testosterone- and estrogen-mediated neuroprotection.</p>
<p id="Par25">To determine if this effect is specific to neuronal-derived cells, we examined the neuroprotective properties of testosterone, 17β-estradiol, and DHT-BSA in C6 glial-derived cells. Similar to N27 cells, this cell line does not contain full-length androgen receptors but does express the androgen receptor variant, AR45 (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). Unlike the N27 cells, neither testosterone (Fig. <xref ref-type="fig" rid="Fig2">2</xref>d) nor estradiol (Fig. <xref ref-type="fig" rid="Fig2">2</xref>e) was protective against H<sub>2</sub>O<sub>2</sub>-induced cell loss in C6 cells. Likewise, DHT-BSA did not protect the cells from H<sub>2</sub>O<sub>2</sub>-induced cell loss (Fig. <xref ref-type="fig" rid="Fig2">2</xref>f).</p>
<p id="Par26">Since the N27 cells are a female-derived cell line, we conducted similar experiments in the PC12 male-derived cell line to examine if sex chromosome complement may underlie this protective effect in neuronal-like cells (Fig. <xref ref-type="fig" rid="Fig3">3</xref>). We observed significant effects of the oxidative stressor H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 24</sub> = 73.64, <italic>η</italic><sup>2</sup> = 0.68, <italic>p</italic> &lt; 0.05) on cell viability, along with an interaction between H<sub>2</sub>O<sub>2</sub> and hormones (<italic>F</italic><sub>2,24</sub> = 3.418, <italic>η</italic><sup>2</sup> = 0.06, <italic>p</italic> &lt; 0.05). Two-hour pretreatment of PC12 cells with testosterone (100 nM) prior to oxidative stress protected the cells by attenuating H<sub>2</sub>O<sub>2</sub>-induced cell loss. In contrast, DHT-BSA did not alter H<sub>2</sub>O<sub>2</sub>-induced cell loss in PC12 cells. These findings are similar to results in the female-derived N27 cells.
<fig id="Fig3"><label>Fig. 3</label><caption><p>Effect of hormone pretreatment in PC12 cells in the presence of oxidative stress. Hormone alone has no effect on cell viability. H<sub>2</sub>O<sub>2</sub> decreased cell viability by ~ 30%. Testosterone pretreatment prior to H<sub>2</sub>O<sub>2</sub> is protective in PC12 cells. DHT-BSA, followed by H<sub>2</sub>O<sub>2</sub> exposure, did not protect PC12 cells in an oxidative stress environment. Results were determined by ANOVA followed by Fisher LSD post hoc test. Results are reported as mean <underline>+</underline> SEM. <italic>p</italic> &lt; 0.05; *versus control, **versus H<sub>2</sub>O<sub>2</sub>. C, vehicle control; T, 100 nM testosterone; H, H<sub>2</sub>O<sub>2</sub>; TH, pre-treatment T; D, 500 nM DHT-BSA; DH, pre-treatment D</p></caption><graphic id="MO3" xlink:href="13293_2020_283_Fig3_HTML"></graphic></fig></p>
<p id="Par27">Interestingly, two different concentrations of H<sub>2</sub>O<sub>2</sub> were necessary to induce 20% cell loss in the cell lines. The N27 and PC12 cells were more sensitive to H<sub>2</sub>O<sub>2</sub> (20–30 uM) than C6 cells to H<sub>2</sub>O<sub>2</sub> (50 uM). This sensitivity to H<sub>2</sub>O<sub>2</sub> may be due to dopamine metabolism of N27 and PC12 cells, which increases the oxidative stress burden and possibly sensitizes the cells to subsequent oxidative stressors [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR74">74</xref>].</p>
</sec>
<sec id="Sec13">
<title>Estrogen receptor mediates neuroprotection</title>
<p id="Par28">Since protection was not observed in C6 cells, we focused on N27 cells for further investigation into the mechanisms underlying hormone-mediated protection. Both testosterone and estradiol were protective against a mild oxidative stress insult that caused 20% cell loss (Fig. <xref ref-type="fig" rid="Fig2">2</xref>a, b), and thus, we wanted to ensure that these hormones would be protective against harsher oxidative stress insults. Therefore, we increased the H<sub>2</sub>O<sub>2</sub> concentration to 50 uM to induce 80% cell loss (Fig. <xref ref-type="fig" rid="Fig4">4</xref>a, b). 17β-estradiol pretreatment significantly protected the cells from oxidative stress-induced cell death (Fig. <xref ref-type="fig" rid="Fig4">4</xref>a), as evidenced by significant effects of H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 8</sub> = 1176.8, <italic>η</italic><sup>2</sup> = 0.93, <italic>p</italic> &lt; 0.05), estradiol (<italic>F</italic><sub>1, 8</sub> = 44.3, <italic>η</italic><sup>2</sup> = 0.03, <italic>p</italic> &lt; 0.05), and an interaction between H<sub>2</sub>O<sub>2</sub> and estradiol (<italic>F</italic><sub>1, 8</sub> = 42.2, <italic>η</italic><sup>2</sup> = 0.03, <italic>p</italic> &lt; 0.05) on cell viability. Similarly, testosterone pretreatment protected N27 cells from H<sub>2</sub>O<sub>2</sub>-induced cell loss (Fig. <xref ref-type="fig" rid="Fig4">4</xref>b), in which significant effects of H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 8</sub> = 877.7, <italic>η</italic><sup>2</sup> = 0.93, <italic>p</italic> &lt; 0.05) and testosterone (<italic>F</italic><sub>1, 8</sub> = 37.7, <italic>η</italic><sup>2</sup> = 0.04, <italic>p</italic> &lt; 0.05), along with an interaction between these two factors (<italic>F</italic><sub>1, 8</sub> = 27.5, <italic>η</italic><sup>2</sup> = 0.03, <italic>p</italic> &lt; 0.05), were observed.
<fig id="Fig4"><label>Fig. 4</label><caption><p>Neuroprotection is via estrogen receptor. 17β-estradiol and testosterone pretreatment prior to oxidative stressor is neuroprotective, regardless of oxidative stress insult (<bold>a</bold>, <bold>b</bold>). Estrogen receptor antagonist, ICI, was able to block 17β-estradiol’s neuroprotective action, but did not impact H<sub>2</sub>O<sub>2</sub>-induced cell loss (<bold>c</bold>). Results were determined by ANOVA followed by Fisher LSD post hoc test. Results are reported as mean <underline>+</underline> SEM. <italic>p</italic> &lt; 0.05; *versus control, **versus H<sub>2</sub>O<sub>2</sub>. C, vehicle control; E, 1 nM 17β-estradiol; H, H<sub>2</sub>O<sub>2</sub>; EH, pre-treatment E; ICI, estrogen receptor antagonist. T, 100 nM testosterone; TH, pre-treatment T</p></caption><graphic id="MO4" xlink:href="13293_2020_283_Fig4_HTML"></graphic></fig></p>
<p id="Par29">To determine if the estrogen receptor is mediating neuroprotection, we blocked the estrogen receptor with ICI that inhibits estrogen α/β receptors [<xref ref-type="bibr" rid="CR75">75</xref>]. We observed significant effects of H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 16</sub> = 210.7, <italic>η</italic><sup>2</sup> = 0.86, <italic>p</italic> &lt; 0.05), estradiol (<italic>F</italic><sub>1, 16</sub> = 15.3, <italic>η</italic><sup>2</sup> = 0.06, <italic>p</italic> &lt; 0.05), and an interaction between H<sub>2</sub>O<sub>2</sub> and estradiol (<italic>F</italic><sub>1, 16</sub> = 11, <italic>η</italic><sup>2</sup> = 0.04, <italic>p</italic> &lt; 0.05) on cell viability (Fig. <xref ref-type="fig" rid="Fig4">4</xref>c). No effects of 17β-estradiol alone were observed. Approximately 20% cell loss was induced by H<sub>2</sub>O<sub>2</sub>. As expected, 17β-estradiol protected the cells from H<sub>2</sub>O<sub>2</sub>’s neurotoxic effects. This neuroprotective effect of estradiol on cell viability was blocked by the co-application of ICI (300 pM, IC50 concentration) with 17β-estradiol prior to H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 16</sub> = 7.2, <italic>η</italic><sup>2</sup> = 0.03, <italic>p</italic> &lt; 0.05), confirming that 17β-estradiol’s neuroprotective effect is through the estrogen α/β receptor (Fig. <xref ref-type="fig" rid="Fig4">4</xref>c).</p>
</sec>
<sec id="Sec14">
<title>Hormone neuroprotection lost when cells are temporarily hormone deficient</title>
<p id="Par30">Even though the FBS media (~ 27.5 pg/ml estradiol) was replaced with CS-FBS media in the prior experiments, cells were always exposed to hormones due to exogenous hormone application (e.g. testosterone, 17β-estradiol) in CS-FBS media. In this set of experiments, N27 cells were incubated in CS-FBS media in the absence of hormones 1 h prior to exogenous hormone (17β-estradiol and testosterone) treatment for 2 h (Fig. <xref ref-type="fig" rid="Fig5">5</xref>). After hormone treatment, cells were exposed to H<sub>2</sub>O<sub>2</sub>. Interestingly, neither 17β-estradiol nor testosterone-protected N27 cells from H<sub>2</sub>O<sub>2</sub>-induced cells loss (Fig. <xref ref-type="fig" rid="Fig5">5</xref>). These results highlight a “window of opportunity” for hormone action, in which hormone deprivation for at least 1 h was sufficient to ameliorate the neuroprotective effects of 17β-estradiol and testosterone against a subsequent oxidative stressor.
<fig id="Fig5"><label>Fig. 5</label><caption><p>Neuroprotection lost after 1-h hormone deprivation. Testosterone and 17β-estradiol had no effect on cell viability, regardless of oxidative stress. H<sub>2</sub>O<sub>2</sub> decreased cell viability by ~ 20% (<bold>a</bold>, <bold>b</bold>). Results were determined by ANOVA followed by Fisher LSD post hoc test. Results are reported as mean <underline>+</underline> SEM. <italic>p</italic> &lt; 0.05; *versus control; C, vehicle control; E, 1 nM 17β-estradiol; H, H<sub>2</sub>O<sub>2</sub>; EH, pre-treatment E; T, 100 nM testosterone; H, H<sub>2</sub>O<sub>2</sub>; TH, pre-treatment T</p></caption><graphic id="MO5" xlink:href="13293_2020_283_Fig5_HTML"></graphic></fig></p>
</sec>
<sec id="Sec15">
<title>Androgens and estrogens are damaging in an oxidative stress environment</title>
<p id="Par31">We previously published that testosterone in an oxidative stress environment is damaging in N27 cells [<xref ref-type="bibr" rid="CR39">39</xref>–<xref ref-type="bibr" rid="CR41">41</xref>]. In this study, testosterone, 17β-estradiol, and DHT-BSA further decreased cell viability in the presence of oxidative stress in both N27 and C6 cells (Fig. <xref ref-type="fig" rid="Fig6">6</xref>). Regardless of cell line, hormone alone did not have any effect on cell viability. In N27 cells, significant effects were observed with H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 8</sub> = 222.6, <italic>η</italic><sup>2</sup> = 0.78, <italic>p</italic> &lt; 0.05), testosterone (<italic>F</italic><sub>1, 8</sub> = 22.4, <italic>η</italic><sup>2</sup> = 0.08, <italic>p</italic> &lt; 0.05), and an interaction between H<sub>2</sub>O<sub>2</sub> and testosterone (<italic>F</italic><sub>1, 8</sub> = 34, <italic>η</italic><sup>2</sup> = 0.12, <italic>p</italic> &lt; 0.05) on cell viability (Fig. <xref ref-type="fig" rid="Fig6">6</xref>a). Estradiol had similar effects as testosterone on N27 cell viability in an oxidative stress environment (Fig. <xref ref-type="fig" rid="Fig6">6</xref>b), as evidenced by significant effects with H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 8</sub> = 129.4, <italic>η</italic><sup>2</sup> = 0.67, <italic>p</italic> &lt; 0.05), 17β-estradiol (<italic>F</italic><sub>1, 8</sub> = 31.9, <italic>η</italic><sup>2</sup> = 0.16, <italic>p</italic> &lt; 0.05), and an interaction between H<sub>2</sub>O<sub>2</sub> and 17β-estradiol (<italic>F</italic><sub>1, 8</sub> = 26.8, <italic>η</italic><sup>2</sup> = 0.14, <italic>p</italic> &lt; 0.05) on cell viability. Consistent with our prior studies [<xref ref-type="bibr" rid="CR41">41</xref>], the membrane androgen receptor agonist, DHT-BSA, exacerbated H<sub>2</sub>O<sub>2</sub>-induced cell loss (Fig. <xref ref-type="fig" rid="Fig6">6</xref>c), as shown by significant effects with H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 8</sub> = 287.2, <italic>η</italic><sup>2</sup> = 0.70, <italic>p</italic> &lt; 0.05), DHT-BSA (<italic>F</italic><sub>1, 8</sub> = 56.2, <italic>η</italic><sup>2</sup> = 0.14, <italic>p</italic> &lt; 0.05), and an interaction between H<sub>2</sub>O<sub>2</sub> and DHT-BSA (<italic>F</italic><sub>1, 8</sub> = 58.1, <italic>η</italic><sup>2</sup> = 0.14, <italic>p</italic> &lt; 0.05). Similar to N27 cells, we observed damaging effects of hormones in an oxidative stress environment in PC12 cells. Significant effects were observed with H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 12</sub> = 88.064, <italic>η</italic><sup>2</sup> = 0.7, <italic>p</italic> &lt; 0.05), DHT-BSA (<italic>F</italic><sub>1, 12</sub> = 11.027, <italic>η</italic><sup>2</sup> = 0.09, <italic>p</italic> &lt; 0.05), and an interaction between H<sub>2</sub>O<sub>2</sub> and DHT-BSA (<italic>F</italic><sub>1, 12</sub> = 14.198, <italic>η</italic><sup>2</sup> = 0.11, <italic>p</italic> &lt; 0.05) on cell viability (Fig. <xref ref-type="fig" rid="Fig7">7</xref>).
<fig id="Fig6"><label>Fig. 6</label><caption><p>Neurotoxic effects of hormones in an oxidative stress environment. Alone, testosterone, 17β-estradiol, and DHT-BSA have no effect on cell viability. H<sub>2</sub>O<sub>2</sub> decreased cell viability by ~ 20%. Testosterone, 17β-estradiol, and DHT-BSA further decreased cell viability in the presence of oxidative stress in N27 cells (<bold>a</bold>–<bold>c</bold>) and C6 cells (<bold>d</bold>–<bold>f</bold>). Results were determined by ANOVA followed by Fisher LSD post hoc test. Results are reported as mean <underline>+</underline> SEM. <italic>p</italic> &lt; 0.05; *versus control, **versus H<sub>2</sub>O<sub>2</sub>. C, vehicle control; T, 100 nM testosterone; H, H<sub>2</sub>O<sub>2</sub>; HT, post-treatment T. E, 1 nM 17β-estradiol; HE, post-treatment E; D, 500 nM DHT-BSA; HD, post-treatment D</p></caption><graphic id="MO6" xlink:href="13293_2020_283_Fig6_HTML"></graphic></fig><fig id="Fig7"><label>Fig. 7</label><caption><p>Neurotoxic effects of hormones in an oxidative stress environment on PC12 cells. Alone, DHT-BSA had no effect on cell viability. H<sub>2</sub>O<sub>2</sub> decreased cell viability by ~ 30%. DHT-BSA further decreased cell viability in the presence of oxidative stress in PC12 cells. Results were determined by ANOVA followed by Fisher LSD post hoc test. Results are reported as mean <underline>+</underline> SEM. <italic>p</italic> &lt; 0.05; *versus control, **versus H<sub>2</sub>O<sub>2</sub>. C, vehicle control; H, H<sub>2</sub>O<sub>2</sub>; D, 500 nM DHT-BSA; HD, post-treatment D</p></caption><graphic id="MO7" xlink:href="13293_2020_283_Fig7_HTML"></graphic></fig></p>
<p id="Par32">Unlike our results that showed only neuroprotection in the N27 cell line, androgens and estrogens exacerbated H<sub>2</sub>O<sub>2</sub>-induced cell loss in the C6 cells. Specifically, testosterone (<italic>F</italic><sub>1, 8</sub> = 383.3, <italic>η</italic><sup>2</sup> = 0.17, <italic>p</italic> &lt; 0.05), H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 8</sub> = 1488.2, <italic>η</italic><sup>2</sup> = 0.66, <italic>p</italic> &lt; 0.05), and an interaction between H<sub>2</sub>O<sub>2</sub> and testosterone (<italic>F</italic><sub>1, 8</sub> = 364.1, <italic>η</italic><sup>2</sup> = 0.16, <italic>p</italic> &lt; 0.05) were observed in C6 cell viability (Fig. <xref ref-type="fig" rid="Fig6">6</xref>d). We observed the same responses with 17β-estradiol (<italic>F</italic><sub>1, 8</sub> = 77.7, <italic>η</italic><sup>2</sup> = 0.15, <italic>p</italic> &lt; 0.05), H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 8</sub> = 341.9, <italic>η</italic><sup>2</sup> = 0.68, <italic>p</italic> &lt; 0.05), and an interaction between the two variables (<italic>F</italic><sub>1, 8</sub> = 77.6, <italic>η</italic><sup>2</sup> = 0.15, <italic>p</italic> &lt; 0.05) on cell viability (Fig. <xref ref-type="fig" rid="Fig6">6</xref>e). Figure <xref ref-type="fig" rid="Fig6">6</xref>f shows the same response with the membrane androgen receptor agonist, DHT-BSA, in which there were significant effects of H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 8</sub> = 109.2, <italic>η</italic><sup>2</sup> = 0.69, <italic>p</italic> &lt; 0.05), DHT-BSA (<italic>F</italic><sub>1, 8</sub> = 23.2, <italic>η</italic><sup>2</sup> = 0.15, <italic>p</italic> &lt; 0.05), and an interaction between oxidative stressor and DHT-BSA (<italic>F</italic><sub>1, 8</sub> = 19, <italic>η</italic><sup>2</sup> = 0.12, <italic>p</italic> &lt; 0.05) on cell viability.</p>
</sec>
<sec id="Sec16">
<title>Cytosolic estrogen and androgen receptors do not mediate hormone toxicity</title>
<p id="Par33">Our prior studies show that inhibiting cytosolic androgen receptors with flutamide, enzalutamide, or bicalutamide does not block androgen’s damaging effects in an oxidative stress environment [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. It is unknown what role estrogen receptors play in the damaging effects of testosterone or estradiol. Since estrogen α/β receptors are involved in neuroprotection (Fig. <xref ref-type="fig" rid="Fig4">4</xref>c), it is possible that these receptors may also mediate their damaging effects. Using N27 cells, ICI did not block testosterone’s negative effects in an oxidative stress environment (Fig. <xref ref-type="fig" rid="Fig8">8</xref>a), as evidence by significant effects of H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 16</sub> = 864.1, <italic>η</italic><sup>2</sup> = 0.67, <italic>p</italic> &lt; 0.05), testosterone (<italic>F</italic><sub>1, 16</sub> = 224.4, <italic>η</italic><sup>2</sup> = 0.17, <italic>p</italic> &lt; 0.05), and an interaction between oxidative stressor and testosterone (<italic>F</italic><sub>1, 16</sub> = 179.8, <italic>η</italic><sup>2</sup> = 0.14, <italic>p</italic> &lt; 0.05) on cell viability but no effects of ICI (<italic>F</italic><sub>1, 16</sub> = 0.152, <italic>η</italic><sup>2</sup> = 0.0001, <italic>p</italic> &gt; 0.05). A similar lack of response was observed with ICI and estradiol in an oxidative stress environment (Fig. <xref ref-type="fig" rid="Fig8">8</xref>b), wherein H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 16</sub> = 347, <italic>η</italic><sup>2</sup> = 0.66, <italic>p</italic> &lt; 0.05), 17β-estradiol (<italic>F</italic><sub>1, 16</sub> = 96.7, <italic>η</italic><sup>2</sup> = 0.18, <italic>p</italic> &lt; 0.05), and an interaction between H<sub>2</sub>O<sub>2</sub> and 17β-estradiol (<italic>F</italic><sub>1, 16</sub> = 66.9, <italic>η</italic><sup>2</sup> = 0.13, <italic>p</italic> &lt; 0.05) had significant effects on N27 cell viability but not ICI (<italic>F</italic><sub>1, 16</sub> = 0.030, <italic>η</italic><sup>2</sup> = 0.00006, <italic>p</italic> &gt; 0.05).
<fig id="Fig8"><label>Fig. 8</label><caption><p>The role of estrogen receptor in hormone-induced neurodegeneration. Estrogen receptor antagonist, ICI, did not prevent testosterone and 17β-estradiol’s detrimental effects after H<sub>2</sub>O<sub>2</sub> exposure in N27 cells (<bold>a</bold>, <bold>b</bold>) and C6 cells (<bold>c</bold>, <bold>d</bold>). Results were determined by ANOVA followed by Fisher LSD post hoc test. Results are reported as mean <underline>+</underline> SEM. <italic>p</italic> &lt; 0.05; *versus control, **versus H<sub>2</sub>O<sub>2</sub>. C, vehicle control; T, 100 nM testosterone; H, H<sub>2</sub>O<sub>2</sub>; HT, post-treatment T. E, 1 nM 17β-estradiol; HE, post-treatment E</p></caption><graphic id="MO8" xlink:href="13293_2020_283_Fig8_HTML"></graphic></fig></p>
<p id="Par34">Likewise, in C6 cells ICI did not block testosterone or estradiol exacerbation of H<sub>2</sub>O<sub>2</sub>-induced cell loss. In Fig. <xref ref-type="fig" rid="Fig8">8</xref>c, C6 cell viability was significantly impacted by H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 16</sub> = 2162.1, <italic>η</italic><sup>2</sup> = 0.63, <italic>p</italic> &lt; 0.05), testosterone (<italic>F</italic><sub>1, 16</sub> = 657.5, <italic>η</italic><sup>2</sup> = 0.19, <italic>p</italic> &lt; 0.05), and an interaction between oxidative stressor and testosterone (<italic>F</italic><sub>1, 16</sub> = 610.5, <italic>η</italic><sup>2</sup> = 0.18, <italic>p</italic> &lt; 0.05), but no effects of ICI (<italic>F</italic><sub>1, 16</sub> = 1.589, <italic>η</italic><sup>2</sup> = 0.0005, <italic>p</italic> &gt; 0.05). Similar effects were found using estradiol in Fig. <xref ref-type="fig" rid="Fig8">8</xref>d, in which we observed significant effects of H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 16</sub> = 1235.5, <italic>η</italic><sup>2</sup> = 0.70, <italic>p</italic> &lt; 0.05), 17β-estradiol (<italic>F</italic><sub>1, 16</sub> = 256.1, <italic>η</italic><sup>2</sup> = 0.15, <italic>p</italic> &lt; 0.05), and an interaction between oxidative stressor and 17β-estradiol (<italic>F</italic><sub>1, 16</sub> = 246.5, <italic>η</italic><sup>2</sup> = 0.14, <italic>p</italic> &lt; 0.05), but no effects of ICI (<italic>F</italic><sub>1, 16</sub> = 0.006, <italic>η</italic><sup>2</sup> = 0.00, <italic>p</italic> &gt; 0.05) in C6 cells.</p>
</sec>
<sec id="Sec17">
<title>Non-genomic mechanisms underlie hormone toxicity</title>
<p id="Par35">Since neither estrogen receptor α/β nor cytosolic androgen receptors mediate hormone toxicity, we focused on the AR45 androgen receptor variant that is expressed in plasma membrane lipid rafts in the CNS [<xref ref-type="bibr" rid="CR42">42</xref>]. We previously published that ASC-J9 (J9), an androgen receptor degrader, was able to protect the N27 cells from testosterone’s damaging effects in an oxidative stress environment [<xref ref-type="bibr" rid="CR39">39</xref>]. However, it is unknown if AR45 mediates androgen toxicity in C6 cells.</p>
<p id="Par36">Similar to our prior studies, degradation of the AR45 via J9 protected N27 cells from testosterone-induced cell loss in the presence of H<sub>2</sub>O<sub>2</sub> (Fig. <xref ref-type="fig" rid="Fig9">9</xref>a). We observed significant effects of H<sub>2</sub>O<sub>2</sub> (<italic>F</italic><sub>1, 16</sub> = 86.2, <italic>η</italic><sup>2</sup> = 0.67, <italic>p</italic> &lt; 0.05), testosterone (<italic>F</italic><sub>1, 16</sub> = 7.5, <italic>η</italic><sup>2</sup> = 0.06, <italic>p</italic> &lt; 0.05), and a significant interaction between H<sub>2</sub>O<sub>2</sub> and testosterone (<italic>F</italic><sub>1, 16</sub> = 10.9, <italic>η</italic><sup>2</sup> = 0.08, <italic>p</italic> &lt; 0.05), along with a significant interaction between H<sub>2</sub>O<sub>2</sub>, testosterone, and AR degrader (<italic>F</italic><sub>1, 16</sub> = 8.8, <italic>η</italic><sup>2</sup> = 0.07, <italic>p</italic> &lt; 0.05). Notably, J9 did not affect H<sub>2</sub>O<sub>2</sub>-induced cell loss, indicating that it does not have off-target scavenging effects at the current concentration in N27 cells.
<fig id="Fig9"><label>Fig. 9</label><caption><p>Androgen receptor degradation blocked testosterone-induced neurodegeneration in N27 cells. Cells were seeded for 24 h, followed by J9 pretreatment for 30 min. At 80% confluency, cells were exposed to H<sub>2</sub>O<sub>2</sub> for 1 h followed by testosterone treatment for 2 h. J9 blocked further exacerbation of H<sub>2</sub>O<sub>2</sub>-induced cell loss in N27 cells (<bold>a</bold>). However, J9 attenuated H<sub>2</sub>O<sub>2</sub>-induced cell loss in C6 cells, and thus, its effect on testosterone could not be determined (<bold>b</bold>). Results were determined by ANOVA followed by Fisher LSD post hoc test. Results are reported as mean <underline>+</underline> SEM. <italic>p</italic> &lt; 0.05; *versus control, **versus H<sub>2</sub>O<sub>2</sub>. C, vehicle control; H, H<sub>2</sub>O<sub>2</sub>; T, 100 nM testosterone; H, H<sub>2</sub>O<sub>2</sub>; HT, post-treatment T; J9, ASC J9</p></caption><graphic id="MO9" xlink:href="13293_2020_283_Fig9_HTML"></graphic></fig></p>
<p id="Par37">We observed different results using C6 cells. Contrary to the observable neuroprotective actions by J9 in N27 cells, J9 acts as a scavenger in C6 cells. Specifically, J9 attenuated H<sub>2</sub>O<sub>2</sub>-induced cell loss (<italic>F</italic><sub>1, 16</sub> = 90, <italic>η</italic><sup>2</sup> = 0.25, <italic>p</italic> &lt; 0.05), and thus, its effect on testosterone could not be determined (Fig. <xref ref-type="fig" rid="Fig9">9</xref>b). A lower dose (1 uM) of J9 was used. However, it was ineffective and did not impact C6 cell viability (data not shown).</p>
</sec>
</sec>
<sec id="Sec18">
<title>Discussion</title>
<p id="Par38">The role of sex hormones, such as androgens and estrogens, on cellular function is unclear. For example, some studies show androgens and estrogens are protective in the CNS. However, other studies found either no effects or damaging effects, especially in oxidative stress environments. Interestingly, sex differences have been observed in multiple oxidative stress-associated CNS disorders, such as Parkinson’s disease [<xref ref-type="bibr" rid="CR47">47</xref>], autism [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>], schizophrenia [<xref ref-type="bibr" rid="CR50">50</xref>], Alzheimer’s disease [<xref ref-type="bibr" rid="CR51">51</xref>], stroke [<xref ref-type="bibr" rid="CR52">52</xref>], major depression [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>], and anxiety disorders [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>], indicating a role for sex hormones. Since it is unclear what impact androgens and estrogens have on oxidative stress signaling, the current study examined the relationship between sex hormones and oxidative stress on cell viability.</p>
<p id="Par39">The major findings of this study are (1) the first evidence of AR45 protein expression in the human brain, (2) testosterone and estrogen are protective against subsequent oxidative stress insults in neuronal-derived cells but not in glial-derived cells, (3) the estrogen receptor α/β mediates sex hormone neuroprotection, (4) a 1-h window of opportunity exists for sex hormone neuroprotection, (5) sex hormone administration following oxidative stress exacerbates oxidative stress damage in neuronal- and glial-derived cells, (6) the estrogen receptor is not involved in sex hormone-mediated toxicity, and (7) AR45 mediates androgen exacerbation of oxidative stress-induced cell loss. Since no differences were observed due to sex chromosome complement (N27 female-derived and PC12 male-derived neuronal phenotypic cells, C6 male-derived glial cells), the observed findings indicate that sex hormones’ cellular effects are not dependent on genotype (XX, XY) but rather are more specific to cell type, receptor profile, and the environmental status of the cell (e.g., oxidative stress load).</p>
<p id="Par40">Although it is known that the full-length androgen receptor is expressed in the hippocampus [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>], our data showed lack of full-length androgen receptor expression in frozen hippocampal postmortem tissue from individuals diagnosed with Alzheimer’s disease (Fig. <xref ref-type="fig" rid="Fig1">1c</xref>). This result is not unexpected, as the full-length androgen receptor protein is known to degrade into fragments (e.g., 70 kDa fragments) under conditions such as freezing [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. Further, the presence of 70 kDa androgen receptor fragment increases with age [<xref ref-type="bibr" rid="CR80">80</xref>]. Interestingly, aging is associated with increased oxidative stress [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Thus, it is a possible oxidative stress may play a role in androgen receptor degradation, as oxidative stress has a bidirectional relationship with calcium-dependent calpain proteases [<xref ref-type="bibr" rid="CR83">83</xref>–<xref ref-type="bibr" rid="CR85">85</xref>] that can cleave full-length androgen receptors into 70 kDa fragments [<xref ref-type="bibr" rid="CR86">86</xref>–<xref ref-type="bibr" rid="CR89">89</xref>]. Future studies will examine if aging and neurodegenerative disorders are associated with increased expression of androgen receptor fragments.</p>
<p id="Par41">The first study on the characterization and distribution of AR45 in humans by Ahrens-Fath 2005 failed to observe AR45 expression in the human brain tissue [<xref ref-type="bibr" rid="CR90">90</xref>]. The Ahrens-Fath study used the whole brain tissue, whereas we used a specific region of the brain tissue (i.e., hippocampus). The Ahrens-Fath study failed to show full-length androgen receptor transcript expression (positive control) in the human brain [<xref ref-type="bibr" rid="CR90">90</xref>], which is widely known to be present in the human brain [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Therefore, the lack of full-length androgen receptor and AR45 transcript expression in the human brain in the Ahrens-Fath study could be a false negative result. Since our data shows that AR45 protein is present in the human brain tissue and does not respond to classical androgen receptor antagonists along with data from Hu [<xref ref-type="bibr" rid="CR91">91</xref>] showing AR45 mRNA expression in the aged human brain tissue, this protein may be an important pharmacological therapeutic target for neurodegenerative conditions.</p>
<p id="Par42">Neuronal- and glial-derived cells responded differently to the oxidative stressor, H<sub>2</sub>O<sub>2</sub>. The neuronal phenotypic N27 and PC12 cell lines were more sensitive to oxidative stress than the glial-derived C6 cells. This result is consistent with several reported studies [<xref ref-type="bibr" rid="CR92">92</xref>–<xref ref-type="bibr" rid="CR94">94</xref>]. Glia cell (e.g., astrocytes and microglia) functions are diverse. They range from maintaining the brain environment [<xref ref-type="bibr" rid="CR95">95</xref>], energy storage, and synaptic maintenance by modulating the neurotransmitter release and uptake (e.g., glutamate and GABA) [<xref ref-type="bibr" rid="CR96">96</xref>–<xref ref-type="bibr" rid="CR101">101</xref>], regulating the action potentials via potassium modulation [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>], and synthesizing and releasing the neurotrophic factors and neurosteroids [<xref ref-type="bibr" rid="CR104">104</xref>–<xref ref-type="bibr" rid="CR107">107</xref>]. These glial cell functions may underlie their resistance to oxidative stress insults.</p>
<p id="Par43">The role of glial cells in neuronal degeneration is of increasing interest. The glia to neuron ratio (GNR) may play a role in the observed sex differences in brain regions linked with oxidative stress-associated diseases. In this study, we reviewed the literature for GNR in various brain regions associated with Alzheimer’s disease, Parkinson’s disease, major depression, anxiety disorders, schizophrenia, and autism spectrum disorders, as these disorders exhibit sex differences in prevalence (Table <xref ref-type="table" rid="Tab2">2</xref>). We generally observed fewer glial cells per neuron in brain regions linked with more male-biased oxidative stress CNS disorders. For example, in the striatum, substantia nigra pars compacta, spinal cord, and cerebellum, neuronal cells far outnumbered glial cells. The presence of fewer glial cells could increase the susceptibility of these brain regions to oxidative stress damage due to the loss of glial supportive mechanisms from oxidative stress damage. Interestingly, testosterone itself is an oxidative stressor [<xref ref-type="bibr" rid="CR39">39</xref>–<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR129">129</xref>]. Our results show that under conditions of oxidative stress, testosterone can exacerbate oxidative stress damage via a membrane-associated androgen receptor (AR45) [<xref ref-type="bibr" rid="CR39">39</xref>–<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR129">129</xref>]. Therefore, androgens could be involved in the observed sex differences in these brain regions.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Glia to neuron ratio (GNR) in various brain regions associated with oxidative stress-related CNS disorders</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Brain region</th><th>GNR</th><th>Citations for GNR</th><th>Associated disorders</th><th>Citations for disorders</th></tr></thead><tbody><tr><td>Cortex (monkey)</td><td>1:1</td><td>[<xref ref-type="bibr" rid="CR108">108</xref>]</td><td rowspan="2"><p>Female bias: AD, MD, ANX</p><p>Male bias: PD, SZ, ASD</p></td><td rowspan="2">[<xref ref-type="bibr" rid="CR109">109</xref>–<xref ref-type="bibr" rid="CR114">114</xref>]</td></tr><tr><td>Cortex (human)</td><td>4:1</td><td>[<xref ref-type="bibr" rid="CR115">115</xref>]</td></tr><tr><td>Cortex (rat)</td><td>1:1</td><td>[<xref ref-type="bibr" rid="CR116">116</xref>]</td><td></td><td></td></tr><tr><td rowspan="2">Striatum (mouse)</td><td rowspan="2">1:17</td><td rowspan="2">[<xref ref-type="bibr" rid="CR117">117</xref>]</td><td>Female bias: MD</td><td rowspan="2">[<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]</td></tr><tr><td>Male bias: PD, SZ, ASD</td></tr><tr><td rowspan="2">Basal ganglia (human)</td><td rowspan="2">1:2</td><td rowspan="2">[<xref ref-type="bibr" rid="CR118">118</xref>]</td><td>Female bias: MD,</td><td rowspan="2">[<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR114">114</xref>]</td></tr><tr><td>Male bias: PD, SZ, ASD</td></tr><tr><td rowspan="2">Substantia nigra pars compacta (mouse)</td><td rowspan="2">1:9</td><td rowspan="2">[<xref ref-type="bibr" rid="CR119">119</xref>]</td><td>Female bias:—</td><td rowspan="2">[<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR120">120</xref>]</td></tr><tr><td>Male bias: PD, SZ</td></tr><tr><td rowspan="2">Thalamus (human)</td><td rowspan="2">17:1</td><td rowspan="2">[<xref ref-type="bibr" rid="CR121">121</xref>]</td><td>Female bias: MD</td><td rowspan="2">[<xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td>Male bias: PD, SZ</td></tr><tr><td>Hippocampus overall (mouse)</td><td>1:1</td><td>[<xref ref-type="bibr" rid="CR117">117</xref>]</td><td><p>Female bias: AD, MD, ANX,</p><p>Male bias: PD, SZ, ASD</p></td><td>[<xref ref-type="bibr" rid="CR109">109</xref>–<xref ref-type="bibr" rid="CR114">114</xref>]</td></tr><tr><td>CA1 (mouse)</td><td>1:2</td><td>[<xref ref-type="bibr" rid="CR117">117</xref>]</td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>CA3 (mouse)</td><td>1:3</td><td>[<xref ref-type="bibr" rid="CR117">117</xref>]</td></tr><tr><td rowspan="2">Locus coeruleus (human)</td><td rowspan="2">27:1</td><td rowspan="2">[<xref ref-type="bibr" rid="CR123">123</xref>]</td><td>Female bias: AD, MD</td><td rowspan="2">[<xref ref-type="bibr" rid="CR110">110</xref>–<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR124">124</xref>, <xref ref-type="bibr" rid="CR125">125</xref>]</td></tr><tr><td>Male bias: PD, ANX</td></tr><tr><td rowspan="2">Amygdala basolateral (rat)</td><td rowspan="2">1:7</td><td rowspan="2">[<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]</td><td>Female bias: AD, MD, ANX,</td><td rowspan="2">[<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR127">127</xref>]</td></tr><tr><td>Male bias: PD, ASD</td></tr><tr><td rowspan="2">Spinal cord (rat)</td><td rowspan="2">1:6</td><td rowspan="2">[<xref ref-type="bibr" rid="CR128">128</xref>]</td><td>Female bias:—</td><td rowspan="2">[<xref ref-type="bibr" rid="CR110">110</xref>]</td></tr><tr><td>Male bias: PD</td></tr><tr><td rowspan="2"><p>Cerebellum (mouse)</p><p>Cerebellum (human)</p></td><td rowspan="2"><p>1:1</p><p>1:4</p></td><td rowspan="2"><p>[<xref ref-type="bibr" rid="CR117">117</xref>]</p><p>[<xref ref-type="bibr" rid="CR115">115</xref>]</p></td><td>Female bias:—</td><td rowspan="2">[<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR114">114</xref>]</td></tr><tr><td>Male bias: PD, ASD</td></tr></tbody></table><table-wrap-foot><p><italic>AD</italic> Alzheimer’s disease, <italic>PD</italic> Parkinson’s disease, <italic>MD</italic> major depression, <italic>ANX</italic> anxiety disorders, <italic>SZ</italic> schizophrenia, <italic>ASD</italic> autism spectrum disorders</p></table-wrap-foot></table-wrap></p>
<p id="Par44">Testosterone’s effects are state dependent. Under low oxidative stress conditions, testosterone and its metabolite 17β-estradiol are neuroprotective via the estrogen receptor. We did not observe protective effects in C6 glial-derived cells. Interestingly, our data showed a window of opportunity for neuroprotection by sex hormones. If neuronal-derived cells were hormone-deficient at least 1 h, neither testosterone nor estrogen protected cells from subsequent oxidative stress insults. These results are consistent with findings from the Women’s Health Initiative concerning the loss of estrogen-mediated protection in menopausal women. Specifically, estrogen was protective in women less than 10 years from menopause [<xref ref-type="bibr" rid="CR130">130</xref>]. Estrogens are associated with decreased homocysteine, a marker of oxidative stress [<xref ref-type="bibr" rid="CR131">131</xref>], in women within 10 years from menopause [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR132">132</xref>]. However, homocysteine levels greater than 8 umol/L in postmenopausal women were associated with negative effects of estrogen [<xref ref-type="bibr" rid="CR133">133</xref>]. Further, homocysteine levels greater than 14 umol/L in individuals over 60 years of age were linked with Alzheimer’s disease risk [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>], which is more prevalent in postmenopausal women [<xref ref-type="bibr" rid="CR11">11</xref>]. Since our results show that estrogens were not protective in an oxidative stress environment, homocysteine levels may be useful as a biomarker for the “window of opportunity” for estrogen protection.</p>
<p id="Par45">The classical cytosolic androgen receptor did not mediate androgen’s effects on neuroprotection, nor did classical androgen receptor antagonists affect androgen-mediated toxicity. Based on these results, medical use of androgen receptor antagonists is unlikely to interfere with androgen’s neuroprotective or damaging effects in neuronal and glial cells. Currently, androgen receptor antagonists are used to treat benign prostatic hyperplasia, prostate cancer, alopecia, hypersexuality, precocious puberty, and transgender transition in men, whereas in women, these drugs are used to treat acne, hirsutism, hyperandrogenism, and amenorrhea.</p>
<p id="Par46">In contrast, the use of estrogen receptor antagonists could have a significant adverse effect by blocking testosterone- and 17β-estradiol-mediated neuroprotection. Currently, estrogen receptor antagonists are used in men and women to treat multiple conditions. Estrogen receptor antagonists are used to treat gynecomastia, breast cancer, and hypogonadism in men; breast cancer, ovulation induction, and transgender transition in women. Notably, the use of estrogen receptor antagonists (i.e., tamoxifen) are associated with increased Parkinson’s disease risk in women [<xref ref-type="bibr" rid="CR136">136</xref>–<xref ref-type="bibr" rid="CR138">138</xref>]. However, the role of estrogen receptor antagonists in Alzheimer’s disease risk in women is less clear [<xref ref-type="bibr" rid="CR139">139</xref>–<xref ref-type="bibr" rid="CR143">143</xref>]. No studies have examined the impact of estrogen receptor antagonists on CNS conditions in men.</p>
</sec>
<sec id="Sec19">
<title>Perspectives and significance</title>
<p id="Par47">The effects of androgens and estrogens on neuronal and glial cell viability are dependent on the cellular environment. In healthy neuronal cells, androgens and estrogens are protective against oxidative stress insults via the estrogen receptor. However, in unhealthy (e.g., high oxidative stress) neuronal and glial cells, sex hormones have negative effects on cell viability by exacerbating oxidative stress-induced cell loss. Additionally, the non-genomic AR45 receptor is involved in androgen’s damaging effects, but it is unknown which receptor mediates estrogen’s damaging effects. These state-dependent effects of sex hormones may mediate the observed sex differences in oxidative stress-associated CNS disorders.</p>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>
<bold>Publisher’s Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>Postmortem tissue was obtained from the Institute for Healthy Aging’s Brain Bank at the University of North Texas Health Science Center. The authors would like to thank Drs. Rosalie Uht and Shaohua Yang of the Institute for Healthy Aging’s Brain Bank for their assistance.</p>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>PD conducted the experiments, analyzed the data, and was a major contributor in writing the manuscript. MAAT helped analyze the data and contribute to writing the manuscript. JT, NR, and CM conducted the experiments. RLC designed the study, interpreted the findings, and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="funding-information">
<title>Funding</title>
<p>This study was supported by the NIH R01 NS0091359 to RLC.</p>
</notes>
<notes notes-type="data-availability">
<title>Availability of data and materials</title>
<p>The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p>
</notes>
<notes>
<title>Ethics approval and consent to participate</title>
<p id="Par48">This study was performed under a human subject protocol approved by the University of North Texas Health Science Center Institutional Review Board.</p>
</notes>
<notes>
<title>Consent for publication</title>
<p id="Par49">Not applicable</p>
</notes>
<notes notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par50">The authors declare that they have no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Darwin</surname>
<given-names>C</given-names>
</name>
</person-group>
<source/>The descent of man, and selection in relation to sex
          <year>1871</year>
<publisher-loc>London, UK</publisher-loc>
<publisher-name>John Murray</publisher-name>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collins</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Varmus</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>A new initiative on precision medicine</article-title>
<source/>N Engl J Med
          <year>2015</year>
<volume>372</volume>
<issue>9</issue>
<fpage>793</fpage>
<lpage>795</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMp1500523</pub-id>
<pub-id pub-id-type="pmid">25635347</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baldereschi</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging</article-title>
<source/>Neurology
          <year>2000</year>
<volume>55</volume>
<issue>9</issue>
<fpage>1358</fpage>
<lpage>1363</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.55.9.1358</pub-id>
<pub-id pub-id-type="pmid">11087781</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baron-Cohen</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Why are autism spectrum conditions more prevalent in males?</article-title>
<source/>PLoS biology
          <year>2011</year>
<volume>9</volume>
<issue>6</issue>
<fpage>e1001081</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pbio.1001081</pub-id>
<pub-id pub-id-type="pmid">21695109</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aleman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Selten</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Sex differences in the risk of schizophrenia: evidence from meta-analysis</article-title>
<source/>Arch Gen Psychiatry
          <year>2003</year>
<volume>60</volume>
<issue>6</issue>
<fpage>565</fpage>
<lpage>571</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.60.6.565</pub-id>
<pub-id pub-id-type="pmid">12796219</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazure</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Swendsen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Sex differences in Alzheimer’s disease and other dementias</article-title>
<source/>Lancet Neurol
          <year>2016</year>
<volume>15</volume>
<issue>5</issue>
<fpage>451</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(16)00067-3</pub-id>
<pub-id pub-id-type="pmid">26987699</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rutter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Caspi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moffitt</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>Using sex differences in psychopathology to study causal mechanisms: unifying issues and research strategies</article-title>
<source/>J Child Psychol Psychiatry
          <year>2003</year>
<volume>44</volume>
<issue>8</issue>
<fpage>1092</fpage>
<lpage>1115</lpage>
<pub-id pub-id-type="doi">10.1111/1469-7610.00194</pub-id>
<pub-id pub-id-type="pmid">14626453</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gobinath</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Choleris</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Galea</surname>
<given-names>LA</given-names>
</name>
</person-group>
<article-title>Sex, hormones, and genotype interact to influence psychiatric disease, treatment, and behavioral research</article-title>
<source/>J Neurosci Res
          <year>2017</year>
<volume>95</volume>
<issue>1-2</issue>
<fpage>50</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.23872</pub-id>
<pub-id pub-id-type="pmid">27870452</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maeng</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Milad</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Sex differences in anxiety disorders: interactions between fear, stress, and gonadal hormones</article-title>
<source/>Horm Behav
          <year>2015</year>
<volume>76</volume>
<fpage>106</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1016/j.yhbeh.2015.04.002</pub-id>
<pub-id pub-id-type="pmid">25888456</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yonkers</surname>
<given-names>KA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronicity, relapse, and illness--course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up</article-title>
<source/>Depress Anxiety
          <year>2003</year>
<volume>17</volume>
<issue>3</issue>
<fpage>173</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="doi">10.1002/da.10106</pub-id>
<pub-id pub-id-type="pmid">12768651</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brinton</surname>
<given-names>RD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Perimenopause as a neurological transition state</article-title>
<source/>Nat Rev Endocrinol
          <year>2015</year>
<volume>11</volume>
<issue>7</issue>
<fpage>393</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="doi">10.1038/nrendo.2015.82</pub-id>
<pub-id pub-id-type="pmid">26007613</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lisabeth</surname>
<given-names>LD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Age at natural menopause and risk of ischemic stroke: the Framingham heart study</article-title>
<source/>Stroke
          <year>2009</year>
<volume>40</volume>
<issue>4</issue>
<fpage>1044</fpage>
<lpage>1049</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.108.542993</pub-id>
<pub-id pub-id-type="pmid">19233935</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haaxma</surname>
<given-names>CA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gender differences in Parkinson’s disease</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2007</year>
<volume>78</volume>
<issue>8</issue>
<fpage>819</fpage>
<lpage>824</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.2006.103788</pub-id>
<pub-id pub-id-type="pmid">17098842</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cereda</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reproductive factors and clinical features of Parkinson’s disease</article-title>
<source/>Parkinsonism Relat Disord
          <year>2013</year>
<volume>19</volume>
<issue>12</issue>
<fpage>1094</fpage>
<lpage>1099</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2013.07.020</pub-id>
<pub-id pub-id-type="pmid">23931933</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ragonese</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Age at menopause predicts age at onset of Parkinson’s disease</article-title>
<source/>Mov Disord
          <year>2006</year>
<volume>21</volume>
<issue>12</issue>
<fpage>2211</fpage>
<lpage>2214</lpage>
<pub-id pub-id-type="doi">10.1002/mds.21127</pub-id>
<pub-id pub-id-type="pmid">17029261</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<mixed-citation publication-type="other">Clayton, A.H. and P.T. Ninan, Depression or menopause? Presentation and management of major depressive disorder in perimenopausal and postmenopausal women. Prim Care Companion J Clin Psychiatry, 2010. 12(1): p. PCC.08r00747.</mixed-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>LY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Risk of psychiatric disorders following symptomatic menopausal transition: a nationwide population-based retrospective cohort study</article-title>
<source/>Medicine (Baltimore)
          <year>2016</year>
<volume>95</volume>
<issue>6</issue>
<fpage>e2800</fpage>
<pub-id pub-id-type="doi">10.1097/MD.0000000000002800</pub-id>
<pub-id pub-id-type="pmid">26871843</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Assalman</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bottlender</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Menopause and schizophrenia</article-title>
<source/>Menopause Int
          <year>2012</year>
<volume>18</volume>
<issue>1</issue>
<fpage>10</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1258/mi.2012.011116</pub-id>
<pub-id pub-id-type="pmid">22308532</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aloysi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Van Dyk</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sano</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Women’s cognitive and affective health and neuropsychiatry</article-title>
<source/>Mt Sinai J Med
          <year>2006</year>
<volume>73</volume>
<issue>7</issue>
<fpage>967</fpage>
<lpage>975</lpage>
<pub-id pub-id-type="pmid">17195882</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<mixed-citation publication-type="other">Mayo Clinic Laboratories. Test ID: ESTF. Estrogens, Estrone (E1) and Estradiol (E2), Fractionated, Serum. 2019 [cited 2019 6/26/2019]; Available from: <ext-link ext-link-type="uri" xlink:href="https://www.mayocliniclabs.com/test-catalog/Clinical+and">https://www.mayocliniclabs.com/test-catalog/Clinical+and</ext-link> + Interpretive/84230.</mixed-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christensen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pike</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Menopause, obesity and inflammation: interactive risk factors for Alzheimer's disease</article-title>
<source/>Front Aging Neurosci
          <year>2015</year>
<volume>7</volume>
<fpage>130</fpage>
<pub-id pub-id-type="doi">10.3389/fnagi.2015.00130</pub-id>
<pub-id pub-id-type="pmid">26217222</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santoro</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Randolph</surname>
<given-names>JF</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<article-title>Reproductive hormones and the menopause transition</article-title>
<source/>Obstet Gynecol Clin North Am
          <year>2011</year>
<volume>38</volume>
<issue>3</issue>
<fpage>455</fpage>
<lpage>466</lpage>
<pub-id pub-id-type="doi">10.1016/j.ogc.2011.05.004</pub-id>
<pub-id pub-id-type="pmid">21961713</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ala-Fossi</surname>
<given-names>SL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ovarian testosterone secretion during perimenopause</article-title>
<source/>Maturitas
          <year>1998</year>
<volume>29</volume>
<issue>3</issue>
<fpage>239</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="doi">10.1016/S0378-5122(98)00034-6</pub-id>
<pub-id pub-id-type="pmid">9699195</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<mixed-citation publication-type="other">Mayo Clinic Laboratories. Test ID: TTFB testosterone, total, bioavailable, and free, serum. 2019 [cited 2019 6/26/2019]; Available from: <ext-link ext-link-type="uri" xlink:href="https://www.mayocliniclabs.com/test-catalog/Clinical+and">https://www.mayocliniclabs.com/test-catalog/Clinical+and</ext-link> + Interpretive/83686.</mixed-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Travison</surname>
<given-names>TG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe</article-title>
<source/>The Journal of Clinical Endocrinology &amp; Metabolism
          <year>2017</year>
<volume>102</volume>
<issue>4</issue>
<fpage>1161</fpage>
<lpage>1173</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2016-2935</pub-id>
<pub-id pub-id-type="pmid">28324103</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nugent</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Hormonally mediated epigenetic changes to steroid receptors in the developing brain: implications for sexual differentiation</article-title>
<source/>Horm Behav
          <year>2011</year>
<volume>59</volume>
<issue>3</issue>
<fpage>338</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="doi">10.1016/j.yhbeh.2010.08.009</pub-id>
<pub-id pub-id-type="pmid">20800064</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impact of sex and hormones on new cells in the developing rat hippocampus: a novel source of sex dimorphism?</article-title>
<source/>Eur J Neurosci
          <year>2008</year>
<volume>27</volume>
<issue>4</issue>
<fpage>791</fpage>
<lpage>800</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2008.06073.x</pub-id>
<pub-id pub-id-type="pmid">18333959</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herbison</surname>
<given-names>AE</given-names>
</name>
</person-group>
<article-title>Sexually dimorphic expression of androgen receptor immunoreactivity by somatostatin neurones in rat hypothalamic periventricular nucleus and bed nucleus of the stria terminalis</article-title>
<source/>J Neuroendocrinol
          <year>1995</year>
<volume>7</volume>
<issue>7</issue>
<fpage>543</fpage>
<lpage>553</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2826.1995.tb00791.x</pub-id>
<pub-id pub-id-type="pmid">7496395</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keil</surname>
<given-names>KP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vivo and in vitro sex differences in the dendritic morphology of developing murine hippocampal and cortical neurons</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>8486</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-08459-z</pub-id>
<pub-id pub-id-type="pmid">28814778</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>H-W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Age- and sex-dependent changes in androgen receptor expression in the developing mouse cortex and hippocampus</article-title>
<source/>Neuroscience Journal
          <year>2015</year>
<volume>2015</volume>
<fpage>11</fpage>
<pub-id pub-id-type="doi">10.1155/2015/525369</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>SF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Androgen receptor in mouse brain: sex differences and similarities in autoregulation</article-title>
<source/>Endocrinology
          <year>1998</year>
<volume>139</volume>
<issue>4</issue>
<fpage>1594</fpage>
<lpage>1601</lpage>
<pub-id pub-id-type="doi">10.1210/endo.139.4.5863</pub-id>
<pub-id pub-id-type="pmid">9528939</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kruijver</surname>
<given-names>FP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sex differences in androgen receptors of the human mamillary bodies are related to endocrine status rather than to sexual orientation or transsexuality</article-title>
<source/>J Clin Endocrinol Metab
          <year>2001</year>
<volume>86</volume>
<issue>2</issue>
<fpage>818</fpage>
<lpage>827</lpage>
<pub-id pub-id-type="doi">10.1210/jcem.86.2.7258</pub-id>
<pub-id pub-id-type="pmid">11158052</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lumbroso</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Immunohistochemical localization and immunoblotting of androgen receptor in spinal neurons of male and female rats</article-title>
<source/>Eur J Endocrinol
          <year>1996</year>
<volume>134</volume>
<issue>5</issue>
<fpage>626</fpage>
<lpage>632</lpage>
<pub-id pub-id-type="doi">10.1530/eje.0.1340626</pub-id>
<pub-id pub-id-type="pmid">8664984</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ravizza</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sex differences in androgen and estrogen receptor expression in rat substantia nigra during development: an immunohistochemical study</article-title>
<source/>Neuroscience
          <year>2002</year>
<volume>115</volume>
<issue>3</issue>
<fpage>685</fpage>
<lpage>696</lpage>
<pub-id pub-id-type="doi">10.1016/S0306-4522(02)00491-8</pub-id>
<pub-id pub-id-type="pmid">12435407</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<mixed-citation publication-type="other">Karlsson, S.A., et al., Neural androgen receptors modulate gene expression and social recognition but not social investigation. Frontiers in Behavioral Neuroscience, 2016. 10(41).</mixed-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pike</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Testosterone attenuates beta-amyloid toxicity in cultured hippocampal neurons</article-title>
<source/>Brain Res
          <year>2001</year>
<volume>919</volume>
<issue>1</issue>
<fpage>160</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(01)03024-4</pub-id>
<pub-id pub-id-type="pmid">11689174</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<mixed-citation publication-type="other">Zárate, S., T. Stevnsner, and R. Gredilla, Role of estrogen and other sex hormones in brain aging. Neuroprotection and DNA Repair. Frontiers in aging neuroscience, 2017. 9: p. 430-430.</mixed-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brinton</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications</article-title>
<source/>Trends Neurosci
          <year>2008</year>
<volume>31</volume>
<issue>10</issue>
<fpage>529</fpage>
<lpage>537</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2008.07.003</pub-id>
<pub-id pub-id-type="pmid">18774188</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tenkorang</surname>
<given-names>MAA</given-names>
</name>
<name>
<surname>Duong</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>NADPH oxidase mediates membrane androgen receptor-induced neurodegeneration</article-title>
<source/>Endocrinology
          <year>2019</year>
<volume>160</volume>
<issue>4</issue>
<fpage>947</fpage>
<lpage>963</lpage>
<pub-id pub-id-type="doi">10.1210/en.2018-01079</pub-id>
<pub-id pub-id-type="pmid">30811529</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress defines the neuroprotective or neurotoxic properties of androgens in immortalized female rat dopaminergic neuronal cells</article-title>
<source/>Endocrinology
          <year>2013</year>
<volume>154</volume>
<issue>11</issue>
<fpage>4281</fpage>
<lpage>4292</lpage>
<pub-id pub-id-type="doi">10.1210/en.2013-1242</pub-id>
<pub-id pub-id-type="pmid">23959938</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of oxidative stress and testosterone on pro-inflammatory signaling in a female rat dopaminergic neuronal cell line</article-title>
<source/>Endocrinology
          <year>2016</year>
<volume>157</volume>
<issue>7</issue>
<fpage>2824</fpage>
<lpage>2835</lpage>
<pub-id pub-id-type="doi">10.1210/en.2015-1738</pub-id>
<pub-id pub-id-type="pmid">27167771</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<mixed-citation publication-type="other">Garza-Contreras, J., et al., Presence of androgen receptor variant in neuronal lipid rafts. eNeuro, 2017. 4(4).</mixed-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCord</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>The evolution of free radicals and oxidative stress</article-title>
<source/>Am J Med
          <year>2000</year>
<volume>108</volume>
<issue>8</issue>
<fpage>652</fpage>
<lpage>659</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9343(00)00412-5</pub-id>
<pub-id pub-id-type="pmid">10856414</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halliwell</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?</article-title>
<source/>Lancet
          <year>1994</year>
<volume>344</volume>
<issue>8924</issue>
<fpage>721</fpage>
<lpage>724</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(94)92211-X</pub-id>
<pub-id pub-id-type="pmid">7915779</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tightly coupled brain activity and cerebral ATP metabolic rate</article-title>
<source/>Proceedings of the National Academy of Sciences
          <year>2008</year>
<volume>105</volume>
<issue>17</issue>
<fpage>6409</fpage>
<pub-id pub-id-type="doi">10.1073/pnas.0710766105</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lepoivre</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide. Relationship to cytostasis induced in tumor cells by cytotoxic macrophages</article-title>
<source/>J Biol Chem
          <year>1994</year>
<volume>269</volume>
<issue>34</issue>
<fpage>21891</fpage>
<lpage>21897</lpage>
<pub-id pub-id-type="pmid">7520445</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress in Parkinson’s disease: a systematic review and meta-analysis</article-title>
<source/>Front Mol Neurosci
          <year>2018</year>
<volume>11</volume>
<fpage>236</fpage>
<pub-id pub-id-type="doi">10.3389/fnmol.2018.00236</pub-id>
<pub-id pub-id-type="pmid">30026688</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossignol</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism</article-title>
<source/>Front Physiol
          <year>2014</year>
<volume>5</volume>
<fpage>150</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2014.00150</pub-id>
<pub-id pub-id-type="pmid">24795645</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<mixed-citation publication-type="other">Chauhan, A. and V. Chauhan, Oxidative stress in autism. Pathophysiology: the official journal of the International Society for Pathophysiology/ISP, 2006. 13(3): p. 171-181.</mixed-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emiliani</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Sedlak</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Oxidative stress and schizophrenia: recent breakthroughs from an old story</article-title>
<source/>Current opinion in psychiatry
          <year>2014</year>
<volume>27</volume>
<issue>3</issue>
<fpage>185</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1097/YCO.0000000000000054</pub-id>
<pub-id pub-id-type="pmid">24613987</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butterfield</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Halliwell</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease</article-title>
<source/>Nature Reviews Neuroscience
          <year>2019</year>
<volume>20</volume>
<issue>3</issue>
<fpage>148</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="doi">10.1038/s41583-019-0132-6</pub-id>
<pub-id pub-id-type="pmid">30737462</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Targeting oxidative stress for the treatment of ischemic stroke: upstream and downstream therapeutic strategies</article-title>
<source/>Brain Circulation
          <year>2016</year>
<volume>2</volume>
<issue>4</issue>
<fpage>153</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="doi">10.4103/2394-8108.195279</pub-id>
<pub-id pub-id-type="pmid">30276293</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michel</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Pulschen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Thome</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The role of oxidative stress in depressive disorders</article-title>
<source/>Curr Pharm Des
          <year>2012</year>
<volume>18</volume>
<issue>36</issue>
<fpage>5890</fpage>
<lpage>5899</lpage>
<pub-id pub-id-type="doi">10.2174/138161212803523554</pub-id>
<pub-id pub-id-type="pmid">22681168</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Black</surname>
<given-names>CN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Is depression associated with increased oxidative stress? A systematic review and meta-analysis</article-title>
<source/>Psychoneuroendocrinology
          <year>2015</year>
<volume>51</volume>
<fpage>164</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2014.09.025</pub-id>
<pub-id pub-id-type="pmid">25462890</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salim</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Oxidative stress and psychological disorders</article-title>
<source/>Current neuropharmacology
          <year>2014</year>
<volume>12</volume>
<issue>2</issue>
<fpage>140</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.2174/1570159X11666131120230309</pub-id>
<pub-id pub-id-type="pmid">24669208</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fedoce</surname>
<given-names>ADG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The role of oxidative stress in anxiety disorder: cause or consequence?</article-title>
<source/>Free Radic Res
          <year>2018</year>
<volume>52</volume>
<issue>7</issue>
<fpage>737</fpage>
<lpage>750</lpage>
<pub-id pub-id-type="doi">10.1080/10715762.2018.1475733</pub-id>
<pub-id pub-id-type="pmid">29742940</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>FS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization and transplantation of two neuronal cell lines with dopaminergic properties</article-title>
<source/>Neurochem Res
          <year>1996</year>
<volume>21</volume>
<issue>5</issue>
<fpage>619</fpage>
<lpage>627</lpage>
<pub-id pub-id-type="doi">10.1007/BF02527762</pub-id>
<pub-id pub-id-type="pmid">8726972</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<mixed-citation publication-type="other">American Type Culture Collection. PC-12 Adh (ATCC® CRL-1721.1™). 2014, July 1; Available from: <ext-link ext-link-type="uri" xlink:href="https://www.atcc.org/products/all/CRL-1721.1.aspx#documentation">https://www.atcc.org/products/all/CRL-1721.1.aspx#documentation</ext-link>.</mixed-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greene</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Tischler</surname>
<given-names>AS</given-names>
</name>
</person-group>
<article-title>Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor</article-title>
<source/>Proceedings of the National Academy of Sciences of the United States of America
          <year>1976</year>
<volume>73</volume>
<issue>7</issue>
<fpage>2424</fpage>
<lpage>2428</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.73.7.2424</pub-id>
<pub-id pub-id-type="pmid">1065897</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benda</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differentiated rat glial cell strain in tissue culture</article-title>
<source/>Science
          <year>1968</year>
<volume>161</volume>
<issue>3839</issue>
<fpage>370</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="doi">10.1126/science.161.3839.370</pub-id>
<pub-id pub-id-type="pmid">4873531</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hubner</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Protective effects of fetal zone steroids are comparable to estradiol in hyperoxia-induced cell death of immature glia</article-title>
<source/>Endocrinology
          <year>2017</year>
<volume>158</volume>
<issue>5</issue>
<fpage>1419</fpage>
<lpage>1435</lpage>
<pub-id pub-id-type="doi">10.1210/en.2016-1763</pub-id>
<pub-id pub-id-type="pmid">28323976</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baumann</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tyrosine hydroxylase binding to phospholipid membranes prompts its amyloid aggregation and compromises bilayer integrity</article-title>
<source/>Scientific reports
          <year>2016</year>
<volume>6</volume>
<fpage>39488</fpage>
<pub-id pub-id-type="doi">10.1038/srep39488</pub-id>
<pub-id pub-id-type="pmid">28004763</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<mixed-citation publication-type="other">Grau, C.M. and L.A. Greene, Use of PC12 cells and rat superior cervical ganglion sympathetic neurons as models for neuroprotective assays relevant to Parkinson’s disease. Methods in molecular biology (Clifton, N.J.), 2012. 846: p. 201-211.</mixed-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okamoto</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mild exercise increases dihydrotestosterone in hippocampus providing evidence for androgenic mediation of neurogenesis</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2012</year>
<volume>109</volume>
<issue>32</issue>
<fpage>13100</fpage>
<lpage>13105</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1210023109</pub-id>
<pub-id pub-id-type="pmid">22807478</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higashi</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Studies on neurosteroids XVIII LC-MS analysis of changes in rat brain and serum testosterone levels induced by immobilization stress and ethanol administration</article-title>
<source/>Steroids
          <year>2006</year>
<volume>71</volume>
<issue>7</issue>
<fpage>609</fpage>
<lpage>617</lpage>
<pub-id pub-id-type="doi">10.1016/j.steroids.2006.03.003</pub-id>
<pub-id pub-id-type="pmid">16620893</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tobiansky</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Testosterone and corticosterone in the mesocorticolimbic system of male rats: effects of gonadectomy and caloric restriction</article-title>
<source/>Endocrinology
          <year>2018</year>
<volume>159</volume>
<issue>1</issue>
<fpage>450</fpage>
<lpage>464</lpage>
<pub-id pub-id-type="doi">10.1210/en.2017-00704</pub-id>
<pub-id pub-id-type="pmid">29069423</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caruso</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparison of plasma and cerebrospinal fluid levels of neuroactive steroids with their brain, spinal cord and peripheral nerve levels in male and female rats</article-title>
<source/>Psychoneuroendocrinology
          <year>2013</year>
<volume>38</volume>
<issue>10</issue>
<fpage>2278</fpage>
<lpage>2290</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2013.04.016</pub-id>
<pub-id pub-id-type="pmid">23706961</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>LeVine</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Albumin and multiple sclerosis</article-title>
<source/>BMC Neurology
          <year>2016</year>
<volume>16</volume>
<issue>1</issue>
<fpage>47</fpage>
<pub-id pub-id-type="doi">10.1186/s12883-016-0564-9</pub-id>
<pub-id pub-id-type="pmid">27067000</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Roos</surname>
<given-names>KL</given-names>
</name>
</person-group>
<source/>Principles of neurologic infectious diseases
          <year>2005</year>
<edition>1</edition>
<publisher-loc>New York</publisher-loc>
<publisher-name>McGraw-Hill Medical Pub. Division</publisher-name>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazer</surname>
<given-names>NA</given-names>
</name>
</person-group>
<article-title>A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: with illustrative examples from male and female populations</article-title>
<source/>Steroids
          <year>2009</year>
<volume>74</volume>
<issue>6</issue>
<fpage>512</fpage>
<lpage>519</lpage>
<pub-id pub-id-type="doi">10.1016/j.steroids.2009.01.008</pub-id>
<pub-id pub-id-type="pmid">19321131</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vermeulen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Verdonck</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kaufman</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>A critical evaluation of simple methods for the estimation of free testosterone in serum</article-title>
<source/>The Journal of clinical endocrinology and metabolism
          <year>1999</year>
<volume>84</volume>
<issue>10</issue>
<fpage>3666</fpage>
<lpage>3672</lpage>
<pub-id pub-id-type="doi">10.1210/jcem.84.10.6079</pub-id>
<pub-id pub-id-type="pmid">10523012</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Estrada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Varshney</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ehrlich</surname>
<given-names>BE</given-names>
</name>
</person-group>
<article-title>Elevated testosterone induces apoptosis in neuronal cells</article-title>
<source/>J Biol Chem
          <year>2006</year>
<volume>281</volume>
<issue>35</issue>
<fpage>25492</fpage>
<lpage>25501</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M603193200</pub-id>
<pub-id pub-id-type="pmid">16803879</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahlbom</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Prins</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Ceccatelli</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism</article-title>
<source/>Brain Res
          <year>2001</year>
<volume>892</volume>
<issue>2</issue>
<fpage>255</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(00)03155-3</pub-id>
<pub-id pub-id-type="pmid">11172772</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lotharius</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>277</volume>
<issue>41</issue>
<fpage>38884</fpage>
<lpage>38894</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M205518200</pub-id>
<pub-id pub-id-type="pmid">12145295</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicholson</surname>
<given-names>RI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer</article-title>
<source/>Ann N Y Acad Sci
          <year>1995</year>
<volume>761</volume>
<fpage>148</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.1995.tb31376.x</pub-id>
<pub-id pub-id-type="pmid">7625718</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simerly</surname>
<given-names>RB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: an in situ hybridization study</article-title>
<source/>J Comp Neurol
          <year>1990</year>
<volume>294</volume>
<issue>1</issue>
<fpage>76</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1002/cne.902940107</pub-id>
<pub-id pub-id-type="pmid">2324335</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<mixed-citation publication-type="other">Dart DA, et al. Visualising androgen receptor activity in male and female mice. PloS one. 2013;8(8):–e71694.</mixed-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kemppainen</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation</article-title>
<source/>Specificity for steroids and antihormones. J. Biol. Chem.
          <year>1992</year>
<volume>267</volume>
<issue>2</issue>
<fpage>968</fpage>
<lpage>974</lpage>
<pub-id pub-id-type="pmid">1730684</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gregory</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>He</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>The putative androgen receptor-A form results from in vitro proteolysis</article-title>
<source/>J Mol Endocrinol
          <year>2001</year>
<volume>27</volume>
<issue>3</issue>
<fpage>309</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="doi">10.1677/jme.0.0270309</pub-id>
<pub-id pub-id-type="pmid">11719283</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>HW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Age- and sex-dependent changes in androgen receptor expression in the developing mouse cortex and hippocampus</article-title>
<source/>Neurosci J
          <year>2015</year>
<volume>2015</volume>
<fpage>525369</fpage>
<pub-id pub-id-type="doi">10.1155/2015/525369</pub-id>
<pub-id pub-id-type="pmid">26317111</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunningham</surname>
<given-names>RL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress, testosterone, and cognition among Caucasian and Mexican-American men with and without Alzheimer’s disease</article-title>
<source/>Journal of Alzheimer’s disease : JAD
          <year>2014</year>
<volume>40</volume>
<fpage>563</fpage>
<lpage>573</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-131994</pub-id>
<pub-id pub-id-type="pmid">24496073</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tenkorang</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Sex-related differences in oxidative stress and neurodegeneration</article-title>
<source/>Steroids
          <year>2018</year>
<volume>133</volume>
<fpage>21</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1016/j.steroids.2017.12.010</pub-id>
<pub-id pub-id-type="pmid">29274405</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ray</surname>
<given-names>SK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress and Ca2+ influx upregulate calpain and induce apoptosis in PC12 cells</article-title>
<source/>Brain Res
          <year>2000</year>
<volume>852</volume>
<issue>2</issue>
<fpage>326</fpage>
<lpage>334</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(99)02148-4</pub-id>
<pub-id pub-id-type="pmid">10678759</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of calpain reduces oxidative stress and attenuates endothelial dysfunction in diabetes</article-title>
<source/>Cardiovasc Diabetol
          <year>2014</year>
<volume>13</volume>
<fpage>88</fpage>
<pub-id pub-id-type="doi">10.1186/1475-2840-13-88</pub-id>
<pub-id pub-id-type="pmid">24886224</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Páramo</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Calpain activation induced by glucose deprivation is mediated by oxidative stress and contributes to neuronal damage</article-title>
<source/>The International Journal of Biochemistry &amp; Cell Biology
          <year>2013</year>
<volume>45</volume>
<issue>11</issue>
<fpage>2596</fpage>
<lpage>2604</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2013.08.013</pub-id>
<pub-id pub-id-type="pmid">23994487</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pelley</surname>
<given-names>RP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Calmodulin-androgen receptor (AR) interaction: calcium-dependent, calpain-mediated breakdown of AR in LNCaP prostate cancer cells</article-title>
<source/>Cancer Res
          <year>2006</year>
<volume>66</volume>
<issue>24</issue>
<fpage>11754</fpage>
<lpage>11762</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2918</pub-id>
<pub-id pub-id-type="pmid">17178871</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mudryj</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tepper</surname>
<given-names>CG</given-names>
</name>
</person-group>
<article-title>On the origins of the androgen receptor low molecular weight species</article-title>
<source/>Hormones &amp; cancer
          <year>2013</year>
<volume>4</volume>
<issue>5</issue>
<fpage>259</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1007/s12672-013-0152-z</pub-id>
<pub-id pub-id-type="pmid">23860689</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Libertini</surname>
<given-names>SJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence</article-title>
<source/>Cancer Res
          <year>2007</year>
<volume>67</volume>
<issue>19</issue>
<fpage>9001</fpage>
<lpage>9005</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-1072</pub-id>
<pub-id pub-id-type="pmid">17909000</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irvine</surname>
<given-names>RA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length</article-title>
<source/>Human Molecular Genetics
          <year>2000</year>
<volume>9</volume>
<issue>2</issue>
<fpage>267</fpage>
<lpage>274</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/9.2.267</pub-id>
<pub-id pub-id-type="pmid">10607837</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahrens-Fath</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Androgen receptor function is modulated by the tissue-specific AR45 variant</article-title>
<source/>FEBS J
          <year>2005</year>
<volume>272</volume>
<issue>1</issue>
<fpage>74</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1111/j.1432-1033.2004.04395.x</pub-id>
<pub-id pub-id-type="pmid">15634333</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>DG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues</article-title>
<source/>Horm Cancer
          <year>2014</year>
<volume>5</volume>
<issue>2</issue>
<fpage>61</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1007/s12672-014-0171-4</pub-id>
<pub-id pub-id-type="pmid">24570075</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwata-Ichikawa</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Glial cells protect neurons against oxidative stress via transcriptional up-regulation of the glutathione synthesis</article-title>
<source/>J Neurochem
          <year>1999</year>
<volume>72</volume>
<issue>6</issue>
<fpage>2334</fpage>
<lpage>2344</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.0722334.x</pub-id>
<pub-id pub-id-type="pmid">10349842</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<mixed-citation publication-type="other">Bhatia, T.N., et al., Astrocytes do not forfeit their neuroprotective roles after surviving intense oxidative stress. Frontiers in Molecular Neuroscience, 2019. 12(87).</mixed-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lassmann</surname>
<given-names>H</given-names>
</name>
<name>
<surname>van Horssen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Oxidative stress and its impact on neurons and glia in multiple sclerosis lesions</article-title>
<source/>Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
          <year>2016</year>
<volume>1862</volume>
<issue>3</issue>
<fpage>506</fpage>
<lpage>510</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2015.09.018</pub-id>
<pub-id pub-id-type="pmid">26432481</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fetler</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Amigorena</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Neuroscience. Brain under surveillance: the microglia patrol</article-title>
<source/>Science
          <year>2005</year>
<volume>309</volume>
<issue>5733</issue>
<fpage>392</fpage>
<lpage>393</lpage>
<pub-id pub-id-type="doi">10.1126/science.1114852</pub-id>
<pub-id pub-id-type="pmid">16020721</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kimelberg</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>High-affinity uptake of serotonin into immunocytochemically identified astrocytes</article-title>
<source/>Science
          <year>1985</year>
<volume>228</volume>
<issue>4701</issue>
<fpage>889</fpage>
<lpage>891</lpage>
<pub-id pub-id-type="doi">10.1126/science.3890180</pub-id>
<pub-id pub-id-type="pmid">3890180</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kimelberg</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Norenberg</surname>
<given-names>MD</given-names>
</name>
</person-group>
<article-title>Astrocytes</article-title>
<source/>Sci Am
          <year>1989</year>
<volume>260</volume>
<issue>4</issue>
<fpage>66</fpage>
<pub-id pub-id-type="doi">10.1038/scientificamerican0489-66</pub-id>
<pub-id pub-id-type="pmid">2564697</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schousboe</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of astrocytic transport processes in glutamatergic and GABAergic neurotransmission</article-title>
<source/>Neurochem Int
          <year>2004</year>
<volume>45</volume>
<issue>4</issue>
<fpage>521</fpage>
<lpage>527</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2003.11.001</pub-id>
<pub-id pub-id-type="pmid">15186918</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boucsein</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Purinergic receptors on microglial cells: functional expression in acute brain slices and modulation of microglial activation in vitro</article-title>
<source/>Eur J Neurosci
          <year>2003</year>
<volume>17</volume>
<issue>11</issue>
<fpage>2267</fpage>
<lpage>2276</lpage>
<pub-id pub-id-type="doi">10.1046/j.1460-9568.2003.02663.x</pub-id>
<pub-id pub-id-type="pmid">12814360</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Light</surname>
<given-names>AR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Purinergic receptors activating rapid intracellular Ca increases in microglia</article-title>
<source/>Neuron Glia Biol
          <year>2006</year>
<volume>2</volume>
<issue>2</issue>
<fpage>125</fpage>
<lpage>138</lpage>
<pub-id pub-id-type="doi">10.1017/S1740925X05000323</pub-id>
<pub-id pub-id-type="pmid">16652167</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>DL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand</article-title>
<source/>J Neurosci
          <year>2005</year>
<volume>25</volume>
<issue>11</issue>
<fpage>2952</fpage>
<lpage>2964</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4456-04.2005</pub-id>
<pub-id pub-id-type="pmid">15772355</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ransom</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Sontheimer</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>The neurophysiology of glial cells</article-title>
<source/>J Clin Neurophysiol
          <year>1992</year>
<volume>9</volume>
<issue>2</issue>
<fpage>224</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="doi">10.1097/00004691-199204010-00005</pub-id>
<pub-id pub-id-type="pmid">1375603</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Reichenbach</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The Muller cell: a functional element of the retina</article-title>
<source/>Trends Neurosci
          <year>1996</year>
<volume>19</volume>
<issue>8</issue>
<fpage>307</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1016/0166-2236(96)10040-0</pub-id>
<pub-id pub-id-type="pmid">8843598</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fawcett</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Asher</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>The glial scar and central nervous system repair</article-title>
<source/>Brain Res Bull
          <year>1999</year>
<volume>49</volume>
<issue>6</issue>
<fpage>377</fpage>
<lpage>391</lpage>
<pub-id pub-id-type="doi">10.1016/S0361-9230(99)00072-6</pub-id>
<pub-id pub-id-type="pmid">10483914</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silver</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Regeneration beyond the glial scar</article-title>
<source/>Nat Rev Neurosci
          <year>2004</year>
<volume>5</volume>
<issue>2</issue>
<fpage>146</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="doi">10.1038/nrn1326</pub-id>
<pub-id pub-id-type="pmid">14735117</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Do Rego</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides</article-title>
<source/>Front Neuroendocrinol
          <year>2009</year>
<volume>30</volume>
<issue>3</issue>
<fpage>259</fpage>
<lpage>301</lpage>
<pub-id pub-id-type="doi">10.1016/j.yfrne.2009.05.006</pub-id>
<pub-id pub-id-type="pmid">19505496</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gatson</surname>
<given-names>JW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aromatase is increased in astrocytes in the presence of elevated pressure</article-title>
<source/>Endocrinology
          <year>2011</year>
<volume>152</volume>
<issue>1</issue>
<fpage>207</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="doi">10.1210/en.2010-0724</pub-id>
<pub-id pub-id-type="pmid">21047944</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dombrowski</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Hilgetag</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Barbas</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Quantitative architecture distinguishes prefrontal cortical systems in the rhesus monkey</article-title>
<source/>Cerebral Cortex
          <year>2001</year>
<volume>11</volume>
<issue>10</issue>
<fpage>975</fpage>
<lpage>988</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/11.10.975</pub-id>
<pub-id pub-id-type="pmid">11549620</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>Imaging the progression of Alzheimer pathology through the brain</article-title>
<source/>Proceedings of the National Academy of Sciences
          <year>2002</year>
<volume>99</volume>
<issue>7</issue>
<fpage>4135</fpage>
<lpage>4137</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.082107399</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caligiore</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Parkinson’s disease as a system-level disorder</article-title>
<source/>NPJ Parkinsons Dis
          <year>2016</year>
<volume>2</volume>
<fpage>16025</fpage>
<pub-id pub-id-type="doi">10.1038/npjparkd.2016.25</pub-id>
<pub-id pub-id-type="pmid">28725705</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandya</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Where in the brain is depression?</article-title>
<source/>Current psychiatry reports
          <year>2012</year>
<volume>14</volume>
<issue>6</issue>
<fpage>634</fpage>
<lpage>642</lpage>
<pub-id pub-id-type="doi">10.1007/s11920-012-0322-7</pub-id>
<pub-id pub-id-type="pmid">23055003</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>EI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology</article-title>
<source/>The Psychiatric clinics of North America
          <year>2009</year>
<volume>32</volume>
<issue>3</issue>
<fpage>549</fpage>
<lpage>575</lpage>
<pub-id pub-id-type="doi">10.1016/j.psc.2009.05.004</pub-id>
<pub-id pub-id-type="pmid">19716990</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>The neuropathology of schizophrenia: a critical review of the data and their interpretation</article-title>
<source/>Brain
          <year>1999</year>
<volume>122</volume>
<issue>4</issue>
<fpage>593</fpage>
<lpage>624</lpage>
<pub-id pub-id-type="doi">10.1093/brain/122.4.593</pub-id>
<pub-id pub-id-type="pmid">10219775</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ha</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characteristics of brains in autism spectrum disorder: structure, function and connectivity across the lifespan</article-title>
<source/>Experimental neurobiology
          <year>2015</year>
<volume>24</volume>
<issue>4</issue>
<fpage>273</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="doi">10.5607/en.2015.24.4.273</pub-id>
<pub-id pub-id-type="pmid">26713076</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herculano-Houzel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The human brain in numbers: a linearly scaled-up primate brain</article-title>
<source/>Frontiers in human neuroscience
          <year>2009</year>
<volume>3</volume>
<fpage>31</fpage>
<pub-id pub-id-type="doi">10.3389/neuro.09.031.2009</pub-id>
<pub-id pub-id-type="pmid">19915731</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herculano-Houzel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dos Santos</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>You do not mess with the glia</article-title>
<source/>Neuroglia
          <year>2018</year>
<volume>1</volume>
<issue>1</issue>
<fpage>193</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.3390/neuroglia1010014</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<mixed-citation publication-type="other">Keller, D., C. Erö, and H. Markram, Cell densities in the mouse brain: a systematic review. Frontiers in Neuroanatomy, 2018. 12(83).</mixed-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>von Bartheld</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Bahney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Herculano-Houzel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The search for true numbers of neurons and glial cells in the human brain: a review of 150 years of cell counting</article-title>
<source/>The Journal of comparative neurology
          <year>2016</year>
<volume>524</volume>
<issue>18</issue>
<fpage>3865</fpage>
<lpage>3895</lpage>
<pub-id pub-id-type="doi">10.1002/cne.24040</pub-id>
<pub-id pub-id-type="pmid">27187682</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smeyne</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Glia cell number modulates sensitivity to MPTP in mice</article-title>
<source/>Glia
          <year>2005</year>
<volume>52</volume>
<issue>2</issue>
<fpage>144</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="doi">10.1002/glia.20233</pub-id>
<pub-id pub-id-type="pmid">15920722</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez-Costas</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Melendez-Ferro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>Basal ganglia pathology in schizophrenia: dopamine connections and anomalies</article-title>
<source/>Journal of neurochemistry
          <year>2010</year>
<volume>113</volume>
<issue>2</issue>
<fpage>287</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.06604.x</pub-id>
<pub-id pub-id-type="pmid">20089137</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pakkenberg</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gundersen</surname>
<given-names>HJ</given-names>
</name>
</person-group>
<article-title>Total number of neurons and glial cells in human brain nuclei estimated by the disector and the fractionator</article-title>
<source/>J Microsc
          <year>1988</year>
<volume>150</volume>
<issue>Pt 1</issue>
<fpage>1</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2818.1988.tb04582.x</pub-id>
<pub-id pub-id-type="pmid">3043005</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halliday</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>Thalamic changes in Parkinson’s disease</article-title>
<source/>Parkinsonism &amp; Related Disorders
          <year>2009</year>
<volume>15</volume>
<fpage>S152</fpage>
<lpage>S155</lpage>
<pub-id pub-id-type="doi">10.1016/S1353-8020(09)70804-1</pub-id>
<pub-id pub-id-type="pmid">20082979</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoogendijk</surname>
<given-names>WJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Image analyser-assisted morphometry of the locus coeruleus in Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis</article-title>
<source/>Brain
          <year>1995</year>
<volume>118</volume>
<issue>Pt 1</issue>
<fpage>131</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="doi">10.1093/brain/118.1.131</pub-id>
<pub-id pub-id-type="pmid">7894999</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giorgi</surname>
<given-names>FS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The neuroanatomy of the reticular nucleus locus coeruleus in Alzheimer’s disease</article-title>
<source/>Frontiers in neuroanatomy
          <year>2017</year>
<volume>11</volume>
<fpage>80</fpage>
<pub-id pub-id-type="doi">10.3389/fnana.2017.00080</pub-id>
<pub-id pub-id-type="pmid">28974926</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prakash</surname>
<given-names>KG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroanatomical changes in Parkinson’s disease in relation to cognition: an update</article-title>
<source/>Journal of advanced pharmaceutical technology &amp; research
          <year>2016</year>
<volume>7</volume>
<issue>4</issue>
<fpage>123</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="doi">10.4103/2231-4040.191416</pub-id>
<pub-id pub-id-type="pmid">27833890</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubinow</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Juraska</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Neuron and glia numbers in the basolateral nucleus of the amygdala from preweaning through old age in male and female rats: a stereological study</article-title>
<source/>The Journal of comparative neurology
          <year>2009</year>
<volume>512</volume>
<issue>6</issue>
<fpage>717</fpage>
<lpage>725</lpage>
<pub-id pub-id-type="doi">10.1002/cne.21924</pub-id>
<pub-id pub-id-type="pmid">19065620</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poulin</surname>
<given-names>SP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Amygdala atrophy is prominent in early Alzheimer’s disease and relates to symptom severity</article-title>
<source/>Psychiatry research
          <year>2011</year>
<volume>194</volume>
<issue>1</issue>
<fpage>7</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1016/j.pscychresns.2011.06.014</pub-id>
<pub-id pub-id-type="pmid">21920712</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bjugn</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gundersen</surname>
<given-names>HJ</given-names>
</name>
</person-group>
<article-title>Estimate of the total number of neurons and glial and endothelial cells in the rat spinal cord by means of the optical disector</article-title>
<source/>J Comp Neurol
          <year>1993</year>
<volume>328</volume>
<issue>3</issue>
<fpage>406</fpage>
<lpage>414</lpage>
<pub-id pub-id-type="doi">10.1002/cne.903280307</pub-id>
<pub-id pub-id-type="pmid">8440788</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>EN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic intermittent hypoxia induces hormonal and male sexual behavioral changes: hypoxia as an advancer of aging</article-title>
<source/>Physiol Behav
          <year>2018</year>
<volume>189</volume>
<fpage>64</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.1016/j.physbeh.2018.03.007</pub-id>
<pub-id pub-id-type="pmid">29526572</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<mixed-citation publication-type="other">Lakryc, E.M., et al., What is the influence of hormone therapy on homocysteine and crp levels in postmenopausal women? Clinics (Sao Paulo, Brazil), 2015. 70(2): p. 107-113.</mixed-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perna</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Ingrosso</surname>
<given-names>D</given-names>
</name>
<name>
<surname>De Santo</surname>
<given-names>NG</given-names>
</name>
</person-group>
<article-title>Homocysteine and oxidative stress</article-title>
<source/>Amino Acids
          <year>2003</year>
<volume>25</volume>
<issue>3-4</issue>
<fpage>409</fpage>
<lpage>417</lpage>
<pub-id pub-id-type="doi">10.1007/s00726-003-0026-8</pub-id>
<pub-id pub-id-type="pmid">14661100</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christodoulakos</surname>
<given-names>GE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Endogenous sex steroids and circulating homocysteine in healthy Greek postmenopausal women</article-title>
<source/>Hormones (Athens)
          <year>2006</year>
<volume>5</volume>
<issue>1</issue>
<fpage>35</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.14310/horm.2002.11166</pub-id>
<pub-id pub-id-type="pmid">16728383</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruschi</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Age, menopausal status and homocysteine levels in women around menopause</article-title>
<source/>Eur J Obstet Gynecol Reprod Biol
          <year>2005</year>
<volume>120</volume>
<issue>2</issue>
<fpage>195</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejogrb.2004.11.016</pub-id>
<pub-id pub-id-type="pmid">15925051</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seshadri</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease</article-title>
<source/>The New England journal of medicine
          <year>2002</year>
<volume>346</volume>
<issue>7</issue>
<fpage>476</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa011613</pub-id>
<pub-id pub-id-type="pmid">11844848</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Malinow</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease</article-title>
<source/>Annu Rev Nutr
          <year>1992</year>
<volume>12</volume>
<fpage>279</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.nu.12.070192.001431</pub-id>
<pub-id pub-id-type="pmid">1503807</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gradus</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The association between adjustment disorder diagnosed at psychiatric treatment facilities and completed suicide</article-title>
<source/>Clin Epidemiol
          <year>2010</year>
<volume>2</volume>
<fpage>23</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.2147/CLEP.S9373</pub-id>
<pub-id pub-id-type="pmid">20865099</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>C-T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tamoxifen and the risk of Parkinson’s disease in female patients with breast cancer in Asian people: a nationwide population-based study</article-title>
<source/>Journal of breast cancer
          <year>2017</year>
<volume>20</volume>
<issue>4</issue>
<fpage>356</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="doi">10.4048/jbc.2017.20.4.356</pub-id>
<pub-id pub-id-type="pmid">29285040</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>HF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tamoxifen usage correlates with increased risk of Parkinson’s disease in older women with breast cancer: a case-control study in Taiwan</article-title>
<source/>Eur J Clin Pharmacol
          <year>2018</year>
<volume>74</volume>
<issue>1</issue>
<fpage>99</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1007/s00228-017-2341-0</pub-id>
<pub-id pub-id-type="pmid">28967041</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<mixed-citation publication-type="other">Liao, K.-F., C.-L. Lin, and S.-W. Lai, Nationwide case-control study examining the association between tamoxifen use and Alzheimer’s disease in aged women with breast cancer in Taiwan. Frontiers in Pharmacology, 2017. 8(612).</mixed-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ording</surname>
<given-names>AG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Null Association between tamoxifen use and dementia in danish breast cancer patients. Cancer Epidemiology Biomarkers &amp;amp</article-title>
<source/>Prevention
          <year>2013</year>
<volume>22</volume>
<issue>5</issue>
<fpage>993</fpage>
<lpage>996</lpage>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henderson</surname>
<given-names>VW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Raloxifene for women with Alzheimer disease: a randomized controlled pilot trial</article-title>
<source/>Neurology
          <year>2015</year>
<volume>85</volume>
<issue>22</issue>
<fpage>1937</fpage>
<lpage>1944</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000002171</pub-id>
<pub-id pub-id-type="pmid">26537053</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yaffe</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial</article-title>
<source/>Am J Psychiatry
          <year>2005</year>
<volume>162</volume>
<issue>4</issue>
<fpage>683</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.162.4.683</pub-id>
<pub-id pub-id-type="pmid">15800139</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>LM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term use of tamoxifen reduces the risk of dementia: a nationwide population-based cohort study</article-title>
<source/>QJM
          <year>2016</year>
<volume>109</volume>
<issue>2</issue>
<fpage>103</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1093/qjmed/hcv072</pub-id>
<pub-id pub-id-type="pmid">25852154</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>